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Summary 
Soil-transmitted helminthiases (STHs) are tropical diseases caused by nematode worms. 
The most common species affecting humans are Ascaris lumbricoides, the hookworms 
(Necator americanus and Ancylostoma duodenale), Trichuris trichiura and Strongyloides 
stercoralis. More than 1 billion people are infected worldwide. Most at risk are the 3 billion 
poorest people of the world, and particularly children. Heavy infections cause iron-deficiency 
anemia, malnutrition, growth stunting and intellectual retardation. STHs occur often 
concomitantly with other infections such as malaria, adding to the disease burden. At 
present, STHs morbidity control relies on chemotherapy, mainly administered within the 
frame of regular mass drug administration campaigns. A tiny panel of five drugs 
(albendazole, mebendazole, levamisole, pyrantel pamoate and ivermectin) is available to 
combat STHs. These present limited efficacies, especially when administered in single dose 
against T. trichiura and hookworm infections. Although anthelmintic drug resistance has not 
yet appeared as a major public health problem, emergence of drug resistance may be 
inevitable in the future. Therefore, the situation is precarious and there is an urgent need for 
new drugs. This has been largely ignored by research. In addition, existing tools for in vitro 
drug sensitivity testing are based on a subjective viability assessment assay which lacks 
convenience and does not allow high-throughput screening rates. Also, the lack of accurate 
diagnostic tools to detect STHs and malaria infections hampers an optimal management of 
these diseases, when it comes to control and eventually eliminate them.  
This work aimed on the one hand to set up nematode-rodent life cycles at the Swiss Tropical 
and Public Health Institute (Swiss TPH), improve drug screening assays and evaluate 
potential new treatments for human STHs. Prior to this thesis, monepantel (AAD 1566), 
tribendimidine, nitazoxanide and oxantel pamoate had been identified as potential drug 
candidates for STHs. On the other hand, we aimed to strengthen our understanding of the 
impact of a murine malaria and hookworm co-infection on the host’s metabolism and explore 
the potential of metabolic profiling as multiplexing diagnostic tool. 
Once the animal models corresponding to human helminthiases have been introduced at the 
Swiss TPH, namely Ancylostoma ceylanicum (at a later stage also N. americanus) and 
Trichuris muris, the Alamar Blue assay, the MTT assay, the acid phosphatase assay, the 
xCELLigence System, isothermal microcalorimetry, and the feeding-inhibition assay (A. 
ceylanicum only) were tested and compared to the current assay of choice, the larval/adult 
motility assay. No assay performed better than the motility assay for drug testing on A. 
ceylanicum third-stage larvae (L3), whereas the xCELLigence System was found as good as 
the adult motility assessment. Using T. muris fourth-stage larvae (L4) or adult worms, the 
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Alamar Blue Assay, the xCELLigence System and isothemal microcalorimetry were found at 
least as useful as the motility assay. 
The potential of monepantel was assessed against A. ceylanicum, N. americanus, T. muris, 
Ascaris suum and Strongyloides ratti. In vivo, the veterinary drug showed good and 
moderate activities respectively, against A. ceylanicum (10 mg/kg: 100% worm burden 
reduction) and N. americanus (10 mg/kg: 58.3% worm burden reduction), but failed to show 
sufficient anthelmintic properties in the other three models.  
Tribendimidine, a Chinese anti-hookworm drug, and its metabolites (dADT and AdADT) were 
tested in vitro and in vivo using the hookworm models A. ceylanicum and Heligmosomoides 
bakeri. Tribendimidine and dADT were found efficacious in both models. In A. ceylanicum-
infected hamsters, single oral doses of 10 mg/kg resulted in 74.8% and 87.4% worm burden 
reduction, respectively. In the T. muris mouse model, single oral doses of 2 mg/kg achieved 
worm burden reductions of 100% and 97.1%, respectively. The second metabolite, AdADT, 
displayed moderate activity against both parasites. The combination tribendimidine-
levamisole displayed an additive to synergistic behavior in the A. ceylanicum model in vivo 
(combination index at ED90 = 0.19). 
Nitazoxanide, an anti-cestodal and anti-protozoal drug was evaluated against A. ceylanicum 
and T. muris. In vitro, it had a marked effect on A. ceylanicum adult worms (IC50 = 0.74 
µg/ml) and on T. muris L3 and adult worms (IC50s = 0.27 and 12.87 µg/ml, respectively). 
However, in both models in vivo no anthelmintic effect was observed. 
The “old” anthelmintic oxantel pamoate was studied in the A. ceylanicum, N. americanus and 
T. muris models. The drug lacked anti-hookworm activity in vivo (10 mg/kg), but showed 
promising trichuricidal properties in vitro and in vivo (ED50 = 4.7 mg/kg). Moreover, the 
combination oxantel pamoate-mebendazole revealed highly synergistic properties. 
Murine H. bakeri and Plasmodium berghei single and co-infection (delayed and 
simultaneous) models were established for metabolic analysis. Urine and plasma samples 
were subjected to 1H nuclear magnetic resonance (NMR) spectroscopy and subsequent 
multivariate analysis in order to identify infection-discriminating metabolic fingerprints. 
Characteristic metabolic fingerprints have been found for each of the infection scenarios. We 
detected two unknown metabolites and confirmed the accumulation of urinary pipecolic acid 
in P. berghei-infected mice, reported in a previous study. Pipecolic acid may therefore 
represent a candidate for human malaria diagnostics.    
In conclusion, for T. muris, one alternative in vitro assay, the Alamar Blue assay, compared 
most favorably to the standard motility assay since it is precise and cost-effective. For         
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A. ceylanicum, no alternative assay was found better than the motility assay for testing on 
L3, whereas the xCELLigence System was found accurate and convenient for adult worms. 
Importantly, out of four examined compounds, one drug has been positively evaluated for its 
trichuricidal properties (oxantel pamoate), one for promising anti-hookworm effects 
(tribendimidine) and two potent drug combinations have been uncovered (tribendimidine-
levamisole and oxantel pamoate-mebendazole), which should be studied in further detail. 
Two drugs failed to show sufficient activity (monepantel and nitazoxanide). 
1H NMR spectroscopy was found powerful for detecting metabolic changes in a co-infection 
model, but still presents some drawbacks as diagnostic tool in its actual form. 
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1. Introduction 
 
 
 
1.1. Soil-transmitted helminthiases 
 
1.1.1. Epidemiology 
Soil-transmitted helminths are gastrointestinal nematode worms that parasitize humans, and 
cause important chronic and debilitating diseases. The most common species are the 
roundworm Ascaris lumbricoides, the hookworms Necator americanus and Ancylostoma 
duodenale, and the whipworm Trichuris trichiura. The threadworm Strongyloides stercoralis 
is the fourth most prevalent soil-transmitted helminth. The global burden of soil-transmitted 
helminthiases (STHs) was revised in 2001, and estimated as high as 1 billion people 
infected [1]. As illustrated in Figure 1, STHs occur primarily in sub-Saharan Africa, Asia, 
Latin America and in the Caribbean [2].  
 
 
Figure 1. The global distribution of Ascaris lumbricoides (a), Trichuris trichiura (b) and hookworm (c). 
White areas represent countries not included in the present analysis. From [2].  
 
Most at risk are the roughly 3 billion most impoverished people living on less than US$ 2 per 
day, particularly school-aged children [3,4]. A. lumbricoides accounts for 807-1221 million 
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the heart). However, S. stercoralis larvae (not eggs) are released with the stools, and the 
parasite has the capacity to re-infect its host (autoinfection). In the host, only female worms 
are present and reproduce by parthenogenesis. Another great difference is that the 
threadworm has a free-living life cycle and can alternate between parasitic and free-living life 
modes [14].  
 
1.1.3. Diagnosis 
Infection with Ascaris, Trichuris, or hookworm is diagnosed by detecting helminth eggs (or 
Strongyloides larvae) in the patient’s stools, using several possible approaches. The method 
recommended by the World Health Organization (WHO) is the Kato-Katz thick smear 
technique [16]. More sensitive and resource-demanding possibilities include the Koga agar 
plate method [17] and the Baermann method [18], especially for the tricky detection of        
S. stercoralis larvae. The ether-concentration method allows the use of larger amounts of 
stools (and detection of concomitant intestinal protozoan infections) [19]. FLOTAC is a 
recent technology, requiring relatively simple laboratory equipment [20]. These techniques 
can also be combined to increase sensitivity. Recent field work identified FLOTAC as more 
sensitive than multiple Kato-Katz thick smears for A. lumbricoides, T. trichiura and 
hookworm eggs [21]. Moreover, FLOTAC can be used for detection of concomitant 
infections by several helminth species and intestinal protozoan parasites, such as Giardia 
intestinalis and Entamoeba spp. [22]. Alternative approaches such as serologic tests 
(enzyme-linked immunosorbent assays, ELISA) have shown risk of cross-reactivity and are 
suboptimal when antibodies persist [23-25]. Polymerase-chain reaction (PCR) methods for 
detecting intestinal helminths are also available and exhibit superior sensitivity compared to 
microscopy [26,27]. However PCR, the method of choice in industrialized countries, has not 
been well-accepted yet, because it necessitates well-equipped laboratories and is less field-
applicable than microscopy. 
 
 
 
1.2. Chemotherapy for the treatment and control of soil-transmitted 
helminthiases 
 
To date, STH control relies essentially on preventive chemotherapy, mainly administered to 
school-aged children or other at-risk groups within the frame of periodic mass drug 
administration (MDA) campaigns [28]. In 2011, a tiny pharmacopeia of five drugs (Figure 4) 
was recommended by the WHO [29]. The benzimidazoles albendazole and mebendazole 
are the first line drugs against ascariasis, trichuriasis and hookworm infections. Pyrantel and 
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levamisole, although not playing prominent roles in preventive chemotherapy, display 
different degrees of efficacy against these three diseases. Ivermectin is used against 
strongyloidiasis, as well as albendazole [28]. In many cases, the drugs are donated by 
pharmaceutical companies, and public-private partnerships (PPPs) [4,30,31].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chemical structures of the standard anthelmintic compounds for treatment of STHs. 
1. Albendazole; 2. Mebendazole; 3. Levamisole; 4. Pyrantel; 5. Ivermectin. 
 
All of the drugs were initially developed for veterinary needs and have been in use in 
humans for decades (Table 1). However, the transitioning into human medicine took place 
without proper adaptation. It has been suggested that the currently applied dosages are 
suboptimal [31]. Many gaps remain in our understanding of the drugs routinely used in MDA 
programs, and in the long term, these knowledge gaps might impair the sustainability of 
treatment efficacy [31]. Moreover, none of these drugs present satisfactory efficacy using 
single doses on all soil-transmitted helminth species, and particularly low efficacy is 
observed against T. trichiura [32]. 
There is currently no new drug in the anthelmintic pipeline for treatment of STHs. In light of 
the alarming status in livestock, there is rising concern about emergence of drug resistance 
in human helminth populations. Relying on only a handful of anthelmintics is a precarious 
situation, and the need for new anthelmintic treatments is acute (new agents or 
combinations of existing drugs).  
STHs are associated with extreme poverty, poor environmental and personal hygiene, and 
therefore other important means to control these diseases exist besides chemotherapy by 
reducing transmission [33]. Health education, access to clean water and sanitation are key 
aspects for moving towards (at least local) STH elimination, as part of socio-economic 
development [34,35]. There is evidence suggesting that urban areas experience significantly 
lower hookworm prevalence, while the situation is reversed for A. lumbricoides and             
T. trichiura [5]. 
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Table 1. Current anthelmintic drugs for treatment of STHs in preventive chemotherapy programs.  
 
1.2.1. Benzimidazole carbamates: albendazole and mebendazole 
The benzimidazoles have proven to be very useful in both veterinary and human medicine. 
They are relatively inexpensive, safe and have a broad spectrum of activity against 
nematodes and other helminths [38]. Currently, albendazole and mebendazole are the two 
most widely used drugs for control and treatment of STHs [32]. As studied for albendazole, 
the benzimidazoles are thought to bind to the free β-tubulin subunits, thus interfering with 
helminth tubulin polymerization [45,46], and thereby leading to progressive cell function 
disruption. Albendazole is largely converted into its more hydrophilic metabolite, albendazole 
sulfoxide, by liver microsomes, and possibly also in the intestine [47,48]. Lipophilicity has 
been shown to facilitate drug diffusion through the nematode cuticle [49,50]. Hence, it has 
been suggested that most nematocidal activity is exerted by the parent drug albendazole, 
complemented by the sulfoxide form [51]. This is in line with the idea that the main route of 
anthelmintic uptake occurs rather by transcuticular diffusion than by oral ingestion by the 
worms [52]. Overall cure rates of ≥94% have been reported after treatment of                      
A. lumbricoides infection with 400 mg albendazole or 500 mg mebendazole using single 
doses [39]. The same doses achieved cure rates of 43.6% and 23.0%, respectively, in T. 
trichiura-infected patients [39]. Mebendazole administered in multiple doses (2x100 mg over 
3 days) has been reported to achieve a median cure rate of approximately 75% [53]. Against 
hookworms, cure rates of 78.4% were observed for 400 mg albendazole, cure rates of only 
22.9% were detected for 500 mg mebendazole [39], and cure rates were approximately 80% 
following treatment with multiple doses of mebendazole (2x100 mg over 3 days) [53]. 
Indications of teratogenicity and embryotoxicity in animal models are the basis for contra-
indications for treatment of children under one year and women in the first trimester of 
pregnancy [48].  
Current anthelmintic treatment options against STHs in preventive chemotherapy programs 
Drug Discovery Incentive Target organisms Adult dosage (oral, single) Reference 
Albendazole 1976 Veterinary 
Ascaris, Trichuris, 
hookworms, 
Strongyloides
400 mg [28,29,36-39] 
Mebendazole 1972 Veterinary Ascaris, Trichuris, hookworms 500 mg [28,29,37-40] 
Levamisole 1969 Veterinary Ascaris, (Trichuris), hookworms 2.5 mg/kg [28,29,38,39,41] 
Pyrantel 
pamoate 1966 Veterinary 
Ascaris, (Trichuris), 
hookworms 10 mg/kg [28,29,38,39,42] 
Ivermectin 1970s Veterinary Strongyloides 3 or 6 mg [28,29,38,39,43,44]
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1.2.2. Nicotinic cholinergic agonists: levamisole and pyrantel pamoate 
Levamisole, an imidazothiazole, and pyrantel pamoate, a tetrahydropyrimidine, act as 
nematode nicotinic acetylcholine receptor (nAChR) agonists. They produce muscle 
contraction and spastic paralysis as a consequence of membrane depolarization by opening 
non-selective cation-channels that are permeable to both Na+ and K+ [54]. The nematode 
muscular AChR are classified into three pharmacological categories, each presenting a 
different channel conductance. The L-subtype is preferentially activated by levamisole, even 
at low concentrations. It has been shown that resistance to levamisole in parasitic 
nematodes is associated with a decrease in response of the L-subtype receptors [55]. 
Levamisole administered at a single oral dose of 2.5 mg/kg, achieved cure rates of 91.5% 
against A. lumbricoides, only 8.6% against T. trichiura, and 38.2% against hookworm [39]. 
Overall cure rates of 87.9%, 28.1% and 87.9% were observed respectively, in                     
A. lumbricoides-, T. trichiura-, or hookworm-infected patients, following a single oral dose of 
10 mg/kg pyrantel pamoate [39].  
 
1.2.3. Macrocyclic lactones: ivermectin 
Ivermectin, the only drug of this class approved for humans, is a potent agent against a wide 
range of nematodes as well as arthropod ectoparasites [31,43]. It is mostly used for the 
treatment and control of infections with filarial parasites (lymphatic filariasis and 
onchocerciasis) and strongyloidiasis [28,32]. Ivermecin displays a low efficacy against 
hookworms, but significantly impacty on Trichuris, whereas controversial findings have been 
reported regarding Ascaris [56-58]. The most likely physiological target is a nematode-
specific glutamate-gated chloride receptor (GluCls) [59]. Ivermectin acts as a potentiator and 
increases the worm muscle Cl- permeability, leading to paralysis and finally, starvation of the 
parasite. At high concentrations, these GluCls are irreversibly and directly opened by the 
drug [54,60]. Although it is the drug of choice for treatment of strongyloidiasis, the treatment 
schedule for ivermectin still has to be defined [44,61]. Ivermectin is rapidly metabolized by 
liver microsomes to several metabolites, and is relatively safe in humans. In vertebrates, 
ivermectin can trigger release of neuronal gamma aminobutyric acid (GABA), but is likely 
prevented from crossing the blood-brain barrier by a P-glycoprotein efflux pump [48].  
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1.3. Drug resistance and lessons from veterinary medicine 
 
1.3.1. Drug resistance 
Drug resistance is defined as an increased proportion of individuals in a parasite population 
that show reduction in sensitivity to a given drug, compared to a normal population [62,63]. It 
can arise following a genetic mutation. Changes at different levels can occur: in the 
molecular target, leading to, for example, a less efficient drug binding; in the metabolism 
resulting in drug detoxication or removal; in the distribution of the drug in the parasite, 
preventing contact between the drug and its target; or amplification of target genes to 
overcome the drug effect [63]. These mutations are inherited, conferring resistance to the 
next generations and no evidence suggests that the phenomenon is reversible [64]. 
Inappropriate treatment use can result in drug resistance. Contributing factors are multiple, 
from under-dosing, sub-optimal targeting and timing of mass treatments, to high treatment 
frequency [65]. Moreover, the treatment frequency, efficacy and pharmacokinetics of the 
drug (fast-acting drugs are safer), as well as the worm’s biology (life-span, fecundity etc.) 
and the environmental conditions, play determining roles in the development of resistance 
[66]. The emergence of drug resistance is no inescapable fate and depends on the relative 
fitness costs attributed to the resistance alleles at the level of drug use [63]. In the case of 
periodic mass treatment, worms that have been excluded from treatment with a given drug 
(refugia) are important in that they “dilute” the resistance alleles with their susceptible ones. 
This is why, according to the prevalence of an infection, it is preferable not to treat the entire 
population [66].  
 
1.3.2. Drug resistance in veterinary medicine 
Drug resistance has evolved as a serious problem against a wide range of parasitic 
nematodes of livestock (i.e. Haemonchus spp., Teladorsagia spp., Trichostrongylus spp.). In 
some countries such as Australia, with high parasite prevalence in sheep, drug resistance 
has arisen against several broad-spectrum drugs of all major families (benzimidazoles, 
nicotinic cholinergic agonists, macrocyclic lactones) [63,67]. Other resistant cases against 
narrow-spectrum drugs (closantel) have also been reported [63]. Drug resistance inflicts 
significant (yet hard to quantify) economic losses to the animal production industry [68]. 
Pasture management and efforts to limit resistance selection pressure are part of the 
strategy to combat these infections, but new drugs are still needed. Monepantel, adding a 
novel mode of action to the arsenal of veterinary anthelmintics, has been the only treatment 
introduced to the market since ivermectin in the late 1970s [69]. However, it is unlikely that 
novel drug classes alone solve the problem of drug resistance, now grown too big [70]. 
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Moreover, with the limited revenues from veterinary drugs, the cost-benefit relationship is 
often seen as financially unrewarding by pharmaceutical companies [71]. 
 
1.3.3. Drug resistance in human soil-transmitted helminth populations 
The recent scale up in chemotherapy programs in numerous geographical regions might 
exert significant drug pressure on soil-transmitted helminth populations [72]. Drug resistance 
in A. lumbricoides populations has not been suspected yet [72]. A few cases of low cure 
rates in human hookworm infections have been recently reported, suggesting for the 
development of drug resistance, but no conclusive evidence is available [65].  
In Mali, N. americanus failed to respond as expected to a single dose of 500 mg 
mebendazole or to 400 mg albendazole, with reported cure rates of 22.9% and 51.4%, 
respectively [73,74]. Surprisingly low efficacies for mebendazole were also reported in 
Vietnam and on Pemba Island (Zanzibar) against hookworms [75,76]. In 2011, albendazole 
showed a high treatment failure rate against hookworms in Ghana [77]. Finally, in Australia, 
a 10 mg/kg pyrantel treatment failed to effectively cure Ancylostoma-infected patients (cure 
rate of 13%) [78]. The number of reports is very limited and based on small groups of 
patients. In addition, without assessing the potential confounding factors, the nature of the 
problem remains uncertain, and could be reflecting either real selection for resistance alleles 
or just reduced efficacy. While likely resistance alleles have been detected in human STHs, 
the frequency of resistance mutations following drug pressure has not been investigated yet 
[72]. An important limiting factor to monitoring emergence of drug resistance in human soil-
transmitted helminth populations is the lack of sensitive diagnostic tools and standardized 
procedures. 
 
 
 
1.4. The need for new treatments 
 
1.4.1. Challenges in anthelmintic drug discovery 
Drug discovery and development is a complicated, costly, risky, time-consuming and highly 
regulated process. The clinical development being the most expensive step, the decision to 
move a compound from discovery into the development phase must be justified by sound 
scientific data and cost considerations [79,80].  
As listed in a proposed target product profile for drugs for STHs, the main characteristics of 
an ideal drug are that it should be cheap, safe and active against at least eggs and adult 
worms of all major geohelminth species and that it should present a novel mode of action. It 
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should be best administered in a single oral dose (or maximum over 2 days) and the 
resulting cure rates should be >90% against adult worms [79].  
The original strategy to discover new anthelmintic compounds was based on direct whole-
organism screening on cultured parasites, or in animals, which presents significant 
drawbacks such as the high cost of random screening relying on animals, or the 
incompatibility with combinatorial chemistry [38]. Therefore, the pharmaceutical industry 
attempted to replace it by an approach named mechanism-based screening [52]. The high 
costs of the equipment needed and the paucity of well-characterized and validated drug 
targets necessary to this screening approach render mechanism-based screening even less 
suitable for anthelmintic research [52,71]. The standard methods for drug sensitivity testing 
on soil-transmitted helminths therefore rely mainly on microscopy for phenotypic assessment 
of a given stage’s viability in vitro and on a range of helminthiases animal models for further 
in vivo investigations. The egg hatch assay tests the ovicidal properties of tested compounds 
[81]. The viability of adult worms or free-living infective larvae is assessed using the motility 
assay, in which the capacity to move is rated on a viability scale or the percent survival is 
calculated [82,83]. These assays are labor-intensive, subjective, and require killing of the 
animal host, for testing on adult worms. Little attention has been given to optimize the 
compound screening strategies, and to date, no assay meets the ideal profile: cheap, 
simple, user-friendly, with an automatized reading. It has to be emphasized that so far, it is 
not possible to culture any parasitic helminth in vitro throughout all the life cycle stages. 
Helminthiases are among the most neglected diseases in terms of drug research and 
development. It has been proposed, that in this situation of very limited resources, few 
candidate drugs and few development partners, a global research and development pipeline 
would be a more efficient strategy than several uncoordinated initiatives. This is why the 
interested public and not-for-profit organizations should build platforms to consistently 
concert their efforts [79]. 
 
1.4.2. Animal models for human soil-transmitted helminthiases 
Animal models have been used extensively to evaluate the potential of drug candidates, 
creating more real-life conditions relating closer reality than in culture systems. A handful of 
rodent models for human STHs have been used in the past decades for drug screening. In 
the frame of this work, we used three hookworm models (Necator americanus, Ancylostoma 
ceylanicum and Heligmosomoides bakeri), a trichuriasis model (Trichuris muris), an 
ascariasis model (Ascaris suum) and a strongyloidiasis model (Strongyloides ratti). A human 
N. americanus and a canine A. ceylanicum have been adapted to hamster hosts over 
decades [84-87]. T. muris is a well-established mouse model [88,89]. A. suum is a murine 
model for the larval stages only and the complete life cycle is maintained in the swine.  
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S. ratti is a rat parasite [90]. Except for A. suum, all the above-mentioned parasites can be 
maintained continuously in the laboratory. 
 
1.4.3. Possible future anthelmintics 
Because veterinary drugs are selected according to very stringent criteria, robust safety, 
pharmacokinetic and efficacy data are usually available and essentially equivalent to human 
requirements. A recent work screened for potential development candidates in the animal 
health arsenal for rapid transitioning into human medicine [79]. Using different publicly 
available information platforms, emodepside, and monepantel have been identified. The old 
drug oxantel, used in the past against T. trichiura, as well as the antiprotozoal drug 
nitazoxanide deserved renewed attention and careful examination of its potential in our 
animal models [91].  
 
1.4.3.1. Cyclooctadepsipeptides 
PF1022A and its semisynthetic derivative emodepside are fungal derivatives displaying 
anthelmintic activity against a range of gastrointestinal nematodes of veterinary importance. 
Both PF1022A and emodepside showed promising efficacy in the threadworm and 
hookworms models S. ratti and H. bakeri after oral treatment, emodepside being slightly 
better [92-94]. The modes of action of the cyclooctadepsipeptides are thought to be both 
interaction with the latrotoxin-induced Ca2+ influx at the latrophilin receptor and relaxation of 
nematodes via Ca2+-activated K+ channels [95]. Treated worms show flaccid paralysis 
followed by death. Importantly, livestock nematode strains that were resistant to the currently 
available drug classes were sensitive to these compounds [95]. In 2005, Bayer Animal 
Health developed emodepside for use in pets against hookworms and ascarids [79]. 
PF1022A has recently been tested against H. bakeri in our laboratory [94]. 
 
1.4.3.2. Tribendimidine 
Tribendimidine, a derivative of the drug amidantel (Bayer) was discovered in the 1980s by 
the Institute of Parasitic Diseases in Shanghai, China [96]. Its anthelmintic properties have 
been determined against numerous laboratory and human helminths. In addition, a rapid 
onset of action and a good reported tolerability contributed to its promising profile [96,97,98]. 
The drug has been approved for human use in China in 2004 to treat hookworm infections 
(N. americanus and A. duodenale) as it performed better with a single oral dose than the 
drug of choice albendazole [39]. In addition, A. lumbricoides in humans as well as S. ratti in 
rodents revealed marked sensitivity [96,98]. Tribendimidine is thought to belong to the L-
subtype nAChR agonists, sharing the same mode of action as levamisole [99].  
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1.4.3.3. Monepantel 
Monepantel (AAD 1566) is an amino-acetonitrile derivative drug developed by Novartis 
Animal Health and was first registered in 2009. Primarily used to treat sheep abomasal and 
intestinal parasites, monepantel is a safe broad-spectrum agent, showing high cure rates on 
fourth stage larvae and adult worms [79]. It has been proposed that the drug interferes with 
nematode-specific nAChR subunits, causing somatic muscle paralysis and thereby resulting 
in death of the worms [69]. It is an agonist of the nematode-specific DEG-3 subtype of 
nAChR, specifically targeting the protein MPTL-1 in H. contortus (or homologs) [69,100]. S. 
ratti lacks this protein and the drug was therefore found inefficacious in this model for STH 
[100]. 
 
1.4.3.4. Nitazoxanide 
Initially described in the 1980s, nitazoxanide is a broad spectrum thiazolide drug with 
anthelmintic, antiprotozoal and antiviral properties [101-103]. It was commercialized more 
than 10 years ago because of its activity against the protozoa Cryptosporidium parvum and 
Giardia intestinalis. A few human clinical trials demonstrated potent nematocidal activity 
following multiple doses of the drug against A. lumbricoides, T. trichiura, A. duodenale, 
Enterobius vermicularis and S. stercoralis [104,105,106]. Nitazoxanide has been shown to 
be a noncompetitive inhibitor of the pyruvate oxydoreductases in protozoa and anaerobic 
bacteria [107]. However, alternative targets such as nitroreductases and protein disulphide 
isomerases have been proposed [103,108]. Nitazoxanide presents an excellent safety and 
bioavailability profile [48,79]. 
 
1.4.3.5. Oxantel  
Oxantel is a meta-oxyphenol derivative of the nicotinic cholinergic agonist pyrantel. 
Discovered in the 1970s by Pfizer, it has been used for treatment of trichuriasis in children, 
while pyrantel lacked efficacy [91]. Experiments with A. suum lead to the classification of  
oxantel as an N-subtype nAChR agonist, like nicotine but unlike levamisole and pyrantel 
[109]. The combination oxantel-pyrantel-praziquantel is widely administered to canines 
against nematodes and cestodes [110]. The combination displayed a poor efficacy (<40%) in 
T. trichiura- and hookworm-infected children in Pemba Island (Zanzibar) [111]. Combinations 
of oxantel with other marketed drugs have not been tested. 
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1.5. Drug combinations 
 
Mathematical modeling revealed a risk reduction of drug resistance development by 
administering several drugs in combination [66]. Combination chemotherapy is now an 
acknowledged strategy against a wide range of pathogens and cancer. In human clinical 
trials, eleven drug combinations of already marketed drugs have been tested so far against 
soil-transmitted helminths and often increased efficacies were obtained (For details, see 
[32]). Combinations of readily approved drugs for human use present the advantage of being 
a “new” treatment, for which introduction to the market might be greatly facilitated. In 
addition, drug combinations help cover a greater range of helminth species, and thus may 
prove to be very useful to treat commonly observed soil-transmitted helminth multiple 
infections [112].  
 
 
 
1.6. The hookworm vaccine 
 
Periodic MDA does not interrupt STHs transmission. In addition, the fact that these worms 
persist in their host for years and that both the prevalence and infection intensity do not 
decrease with age despite regular exposure (at least for hookworms) indicate that humans 
fail to develop protective immunity [113]. In 2000, the Human Hookworm Vaccine Initiative 
was created following concerns about mebendazole drug failure against hookworms and 
potential emergence of drug resistance to the benzimidazoles as well as the rapid re-
infection after treatment [114]. Two human hookworm vaccines have been tested in clinical 
trials. A first recombinant candidate vaccine was based on N. americanus ASP2 
Ancylostoma-secreted protein 2, an antigen secreted by third-stage larvae upon invasion of 
the host [114,115]. It was found safe and immunogenic in unexposed volunteers, but lead to 
adverse events in some patients in a field study. These pre-exposed patients presented high 
levels of IgE against ASP2 [114]. Trials with ASP2 as vaccine antigen were therefore 
discontinued. Since then, hookworm vaccine preclinical research has focused on the 
antigens GST1 (a glutathione-S-transferase) and APR1 (an aspartic protease) used in 
combination in a bivalent product. Both proteins play a role in the adult worms nutritional and 
metabolic requirements [114]. Such a vaccine, conferring modest protection in animal 
models could be cost-effective, even if periodic anthelmintic administration would need to be 
continued [115-117]. To date, no vaccine against other STHs is in development.  
 
  Chapter 1  
26 
 
1.7. Co-infection of soil-transmitted helminths with Plasmodium 
falciparum malaria 
 
It is widely known that helminth infections often occur concomitantly with other endemic 
diseases. Co-infections with several soil-transmitted helminth species are very frequent. 
Extremely common as well, especially in sub-Saharan Africa, is the co-infection of 
hookworms and the malaria causative agent Plasmodium falciparum (Figure 5) [118]. This 
co-infection will be discussed in greater detail here as investigated in the framework of this 
PhD thesis. Among parasitic diseases, P. falciparum inflicts the heaviest burden [119]. In 
2010, it accounted for more than 600,000 deaths globally, mostly among African children 
[120]. Of the approximately 180 million children living on the African continent, an estimated 
50 million are infected with hookworms, and 45 million are considered at risk of concomitant 
infection with malaria (Figure 5) [118]. Besides a documented increase in anemia caused by 
both parasites [121], the rare published reports on the interactions between both infections 
are controversial. Hookworm infections were often associated with increased P. falciparum 
malaria [122-128], but a lack of association was also described [129]. Despite these 
conflicting findings, a tendency for hookworm infections to worsen the pathogenesis of 
malaria has been identified [130]. More specifically, hookworm infections were mostly 
associated with negative effects such as increased incidence and prevalence of malaria 
[122,131] and increased anemia [121]. It has been hypothesized that besides 
immunomodulation, hookworm-induced blood loss might increase the attracting signals to 
malaria mosquito vectors (lactate, increased respiratory rate etc.), resulting in a greater 
probability of getting infected [131]. At the molecular level, both pathogens are thought to 
induce significant immunomodulation, affecting the Th1/Th2 balance of immune responses 
and the capacity to respond to single parasites [127,132]. At present, much remains to be 
discovered about the complex hookworm-malaria-human host interactions. In this work, we 
used a 1H NMR-based metabolic profiling approach to characterize single- and co-infection-
related biomarkers in plasma and urine from a murine model.  
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NMR spectra provide 3 categories of structural information:  
 
1) Electron density and the degree of electron shielding: Each CH group within a molecule is 
represented on a particular position on a chemical shift scale (in parts per million) which is 
dependent on the electronic environment i.e. the electron density surrounding the CH group 
and the resulting degree of shielding, but independent of the field strength [142,143]. The 
more exposed (unshielded) a CH group is, the higher up the chemical shift scale it will be 
found.  
 
2) Neighboring CH group: All CH groups within a molecule are represented by a distinctive 
spectral pattern. The spin-spin coupling (or J coupling) is mediated by chemical bonds 
between CH groups and is indicative of the amount of protons in the neighbor CH group 
[142]. The peak multiplicity represents the number of neighbor 1H groups plus one. 
 
3) CH ratio: NMR spectroscopy can be a quantitative method, and the peak intensities are 
proportional to the number of 1H within one molecule.  
 
A reference compound is usually included, such as sodium 3-(trimethylsilyl) [2,2,3,3-2H4] 
propionate (TSP) which is located at the chemical shift position 0 ppm. 
 
Multivariate analysis (or chemometrics) allows for the identification of inter-group differences 
[144], whereby principal component analysis (PCA) is the most widely applied method for 
initial screening of a data set. As an unsupervised method, it is used to visualize data 
clustering, systematic variation (i.e. over time) and outliers by projecting a cloud of 
coordinates into an n-dimensional space [139,144]. To do so, all information from one 
spectrum is compressed into a single data point placed and projected onto a two-
dimensional plane whereby each axis or principal component (PC) represents a linear 
combination of the original spectral descriptors [143]. Projection to latent structure (PLS) is a 
supervised method and is the method of choice for identifying those metabolites which are 
responsible for class separation (i.e. biomarkers represented by loadings). Here, the concept 
of the statistical analysis is to relate the spectral information in an x-matrix (descriptor) to a 
second matrix (y, the response matrix) containing class information or other, continuous 
measures such as weight, cytokine levels, etc. [145]. Projection to latent structure-
discriminant analysis (PLS-DA) enables class separation and effective subsequent 
biomarker recovery [146]. The orthogonal projection to latent structure-discriminant analysis 
(O-PLS-DA) contains an orthogonal data filter to eliminate systematic variation, such as 
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noise, unrelated to infection status. The method produces correlation coefficient plots (Figure 
7) enabling identification of the discriminating features in the spectral information [145].  
 
 
Figure 7. O-PLS-DA coefficient plot derived from 1H NMR spectra of urine individually collected from 
mice 16 days post-infection with P. berghei (upper part of the graph) versus uninfected controls (lower 
part of the graph). 
 
Metabolic profiling has already been broadly used to gain knowledge about host-parasite 
interactions, with the aim of discovering infection-related specific metabolic markers (< 1 
kDa) and improving diagnostic and disease monitoring capacities [135,138,147-149]. 
However, the use of metabolic profiling for disease monitoring is not yet established and 
further solid animal data are needed [150]. Metabolic profiles from a malaria murine model 
and an N. americanus hamster model have already been studied [138,151], but no co-
infection model between them has been established yet. 1H NMR-based metabonomics 
represents an ideal approach to study the malaria-hookworm-host interactions. 
 
 
 
1.9. Aim and objectives 
 
Novel anthelmintics are urgently needed for treatment of STHs. Only a handful of drugs are 
recommended by the WHO (albendazole, mebendazole, levamisole, pyrantel pamoate and 
ivermectin), most often with insufficient efficacy when administered in single dose. Although 
anthelmintic drug resistance has not yet appeared as a major public health problem, 
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emergence of drug resistance may be inevitable in the future. The need for drugs has been 
largely ignored by research and existing tools for in vitro drug sensitivity testing lack 
convenience and high-throughput screening ability.  
This work aimed on the one hand to improve drug screening capacities and identify potential 
new treatments for STHs. On the other hand, we aimed to strengthen our understanding of 
the impact of a murine malaria and hookworm co-infection on the host’s metabolism and 
identify potential candidate diagnostic biomarkers.  
 
The following objectives were accomplished: 
 
1. To establish the life cycles and nematode rodent models of A. ceylanicum, N. americanus 
and T. muris at the Swiss TPH.  
 
2. To test and optimize a range of different in vitro drug sensitivity assays for A. ceylanicum 
(chapter 2a) and T. muris larvae and adult worms (chapter 2b). 
 
3. To evaluate the potential of the veterinary anthelmintic monepantel (AAD 1566) in five 
animal models for human helminthiases: A. ceylanicum, N. americanus, T. muris, A. suum 
and S. ratti (chapter 3). 
 
4. To compile comprehensive efficacy data on the Chinese anti-hookworm tribendimidine 
against A. ceylanicum and H. bakeri, alone or in combination with the five standard drugs 
(chapter 4). 
 
5. To assess the nematocidal properties of the broad-spectrum drug nitazoxanide against A. 
ceylanicum and T. muris, singly or combined with the five marketed anthelmintics (chapter 
5). 
 
6. To spotlight the forgotten properties of the old drug oxantel by generating data in the 
hookworm (A. ceylanicum and N. americanus) and whipworm (T. muris) rodent models, 
alone or as a partner drug in several combinations with standard anthelmintics (chapter 6). 
 
7. To identify plasma and urinary metabolic fingerprints related to P. berghei and H. bakeri 
single and co-infections, in a murine model (chapter 7). 
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Abstract 
Background: It is widely recognized that only a handful of drugs are available against soil-
transmitted helminthiases, which are characterized by a low efficacy against Trichuris 
trichiura, when administered as single doses. The re-evaluation of old, forgotten drugs is a 
promising strategy to identify alternative anthelminthic drug candidates or drug combinations.  
Methodology: We studied the activity of the veterinary drug oxantel pamoate against 
Trichuris muris, Ancylostoma ceylanicum and Necator americanus in vitro and in vivo. In 
addition, the dose-effect of oxantel pamoate combined with albendazole, mebendazole, 
levamisole, pyrantel pamoate and ivermectin was studied against T. muris in vitro and 
combinations behaving additive or synergistic were followed up in vivo. 
Principal Findings: We calculated an ED50 of 4.7 mg/kg for oxantel pamoate against T. 
muris in mice. Combinations of oxantel pamoate with pyrantel pamoate behaved 
antagonistically in vitro (combination index (CI)=2.53). Oxantel pamoate combined with 
levamisole, albendazole and ivermectin using ratios based on their ED50s revealed 
antagonistic effects in vivo (CI=1.27, 1.90 and 1.27, respectively). A highly synergistic effect 
(CI=0.15) was observed when oxantel pamoate-mebendazole was administered to T. muris-
infected mice. Oxantel pamoate (10 mg/kg) lacked activity against Ancylostoma ceylanicum 
and Necator americanus in vivo.  
Conclusion/Significance: Our study confirms the excellent trichuricidal properties of oxantel 
pamoate. Since the drug lacks activity against hookworms it is necessary to combine oxantel 
pamoate with a partner drug with anti-hookworm properties. Synergistic effects were 
observed for oxantel pamoate-mebendazole, hence this combination should be studied in 
more detail. Since of the standard drugs albendazole has the highest efficacy against 
hookworms additional investigations on the combination effect of oxantel pamoate-
albendazole should be launched.   
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Author Summary 
The roundworm Ascaris lumbricoides, the whipworm Trichuris trichiura and the hookworms 
are responsible for the most common infections worldwide and place more than 5 billion 
people at risk. To control these infections, at risk populations are treated regularly with 
anthelminthic drugs, mostly albendazole and mebendazole. Since both drugs have a low 
therapeutic effect against T. trichiura alternative drugs should be discovered and developed. 
Possible strategies are to re-evaluate forgotten compounds and to thoroughly study drug 
combinations. We evaluated the activity of the “old”, veterinary drug oxantel pamoate against 
T. muris, Ancylostoma ceylanicum and Necator americanus in vitro and in vivo. In addition, 
we studied the activity of combinations of oxantel pamoate with the 4 standard treatments for 
soil-transmitted helminthiases. Our results confirm that oxantel pamoate has excellent 
trichuricidal properties. We show that the drug lacks activity against hookworms. It is 
therefore necessary to combine oxantel pamoate with an anti-hookworm drug. Synergistic 
effects were observed with oxantel pamoate-mebendazole in our study. Additional preclinical 
studies should be launched.  
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1. Introduction 
Infections with the three major soil-transmitted helminths (STH), Ascaris lumbricoides, 
Trichuris trichiura and the hookworms Necator americanus and Ancylostoma duodenale are 
among the most common parasitic diseases in areas of rural poverty in developing countries 
[1]. In countries where soil-transmitted helminthiases are endemic, preventive chemotherapy, 
i.e. regular anthelminthic drug administration to all people at risk of morbidity, is one of the 
key strategies [2]. In 2009 the number of school-aged children treated for soil-transmitted 
helminthiases was estimated at 204 million [3]. Albendazole and mebendazole, 2 drugs 
belonging to the benzimidazole group are the most widely used drugs in preventive 
chemotherapy programs. At present, 2 alternative drugs, pyrantel pamoate and levamisole 
are available but currently have a less prominent role since they require weight-based dosing 
[4]. Despite their excellent safety profile the drugs have serious limitations with regard to their 
efficacy. When delivered as a single dose, as in preventive chemotherapy programs, all 4 
compounds have a limited effect against infections with T. trichiura as calculated by a recent 
meta-analysis [5]. In addition, drug resistance is a concern. Efforts are therefore ongoing to 
discover and develop the next generation of anthelminthic drugs [6]. Promising strategies to 
identify potential anthelminthic drug candidates are to assess compounds derived from 
animal health, to re-evaluate forgotten compounds and to thoroughly study drug 
combinations [6].  
Oxantel is the meta-oxyphenol analog of pyrantel. It was discovered in the early 1970s by 
Pfizer and showed high activity in T. muris-infected mice and T. vulpis-infected dogs [7, 8]. 
Subsequent clinical trials demonstrated that the drug was safe and effective in the treatment 
of trichuriasis [9-12]. For example, complete cure was observed in 10 T. trichiura-infected 
patients treated with 20 mg/kg oxantel pamoate [9]. In veterinary medicine oxantel pamoate 
was later combined with pyrantel pamoate, which has with the exception of activity against 
Trichuris spp. a broad spectrum of activity against different nematodes [13]. Today oxantel-
pyrantel is widely available as a dewormer for dogs and cats. The combination of oxantel-
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pyrantel was also evaluated in a few clinical trials against human STH infections [11, 14-16]. 
For example, a decade ago oxantel-pyrantel (10 mg/kg) was tested in school aged children in 
Pemba. The combination achieved cure rates of 38.2% and 12.7% against infections with T. 
trichiura and hookworms, respectively [17]. To our knowledge, despite the interesting 
trichuricidal properties of oxantel, combinations of this drug with other recommended 
anthelminthic drugs have not been evaluated to date.   
The aim of the present study was to study the trichuricidal potential of oxantel pamoate 
combined with the 4 WHO recommended anthelminthic drugs for the treatment of hookworm, 
T. trichiura and A. lumbricoides infections (albendazole, mebendazole, levamisole or pyrantel 
pamoate) as well as combinations of ivermectin and oxantel pamoate. Ivermectin, the first 
line drug for strongyloidiasis, is known to have trichuricidal properties and combinations of 
albendazole-ivermectin and mebendazole-ivermectin have been tested clinically [18]. In a 
first step the EC50 (ED50) values of oxantel pamoate against T. muris were determined in vitro 
and in vivo. Next to oral administration we also tested the activity of intraperitoneal oxantel 
pamoate in mice. We then elucidated whether oxantel pamoate combined with albendazole, 
mebendazole, ivermectin, levamisole or pyrantel interacts in an additive, antagonistic or 
synergistic manner in vitro using the combination index equation [19]. Additive and 
synergistic combinations were followed up in vivo. In addition, the activity of oxantel pamoate 
was studied against A. ceylanicum and N. americanus in vitro and in vivo. 
 
 
2. Materials and Methods 
 
2.1. Drugs 
Albendazole and levamisole were purchased from Fluka (Buchs, Switzerland), oxantel 
pamoate, mebendazole, ivermectin and pyrantel pamoate were obtained from Sigma-Aldrich 
 
Chapter 6 
100 
 
(Buchs, Switzerland). Note that, the pamoate salts of oxantel and pyrantel contain only 
35.8% and 34.7% of the active ingredients, oxantel and pyrantel base, respectively.  
For in vitro studies, drug stocks (5-10 mg/ml) were prepared in 100% DMSO (Sigma-Aldrich, 
Buchs, Switzerland) and stored at 4°C pending usage. For in vivo studies, the drugs were 
suspended in 10% Tween 80 [80% EtOH (70:30 v/v)] (Buchs, Switzerland) and 90% dH2O 
shortly before treatment.  
 
2.2. Animals  
Four week-old female C57BL/10 mice and 3 week-old male Syrian golden hamsters were 
purchased from Charles River (Blackthorm, UK and Sulzfeld, Germany, respectively). Before 
infection, animals were allowed to acclimatize for one week in our animal facility. They were 
kept in groups of maximum ten (mice) or three (hamsters) in macrolon cages with free 
access to water and rodent food pellets (Rodent Blox from Eberle NAFAG, Gossau, 
Switzerland). 
 
2.3. Ethics statement 
Experiments were performed in an attempt to comply with the 3R rules for animal 
experiments. The current study was approved by the cantonal veterinary office Basel-Stadt 
(Switzerland) based on Swiss cantonal and national regulations (permission no. 2070).  
 
2.4. Parasites and infections 
2.4.1. Trichuris muris 
The life cycle of T. muris has been maintained at the Swiss TPH since January 2010, and 
described in detail in previous publications [20-23]. Mice were treated with dexamethasone (1 
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mg/l, dexamethasone-water soluble, Sigma-Aldrich) supplied with the drinking water 2 days 
before infection onwards and were infected orally with 200 embryonated T. muris eggs.  
 
2.4.2. Ancylostoma ceylanicum and Necator americanus 
The A. ceylanicum and N. americanus life cycles have been maintained at the Swiss TPH 
since June 2009 and April 2011, respectively, and have been described previously [23, 24, 
25, 26]. Hamsters were treated with 0.5 mg/l dexamethasone in the drinking water, 2 days 
before infection onwards. They were infected orally with 150 L3 (A. ceylanicum) or 
subcutaneously with 250 L3 (N. americanus). Hamsters assigned to in vivo studies were not 
immunosuppressed and were infected with 300 L3.  
 
2.5. In vitro studies with Trichuris muris 
2.5.1. Oxantel monotherapy 
Three to 4 fourth-stage larvae (L4) (days 26-28 p.i.) were collected from the intestines 
(binocular, magnification 16x) and transferred into each well of a 96-well plate containing 100 
µl pre-warmed RPMI medium [10.44 g RPMI 1640 (Gibco, Basel, Switzerland), 5 g albumax 
H (Gibco), 5.94 g HEPES (Sigma-Aldrich) and 2.1 g sodium bicarbonate (Sigma-Aldrich) in 1 
l dH2O] supplemented with 5% v/v amphotericin B (250 µg/ml, Sigma-Aldrich) and 1% v/v 
penicillin-streptomycin (10’000 U/ml penicillin + 10 mg/ml streptomycin, Sigma-Aldrich). One 
hundred µl of an oxantel pamoate solution were added to obtain 0.15-600 µg/ml (final 
concentrations) and the plate was incubated at 37°C and 5% CO2 for 72 hours. Control 
worms were incubated in medium with the highest DMSO concentration used in the test (1% 
v/v). After 24, 48 and 72 hours of incubation the viability of the worms was evaluated 
according to a motility scale from 3 to 0 (3=normal, 100% motility, 0=dead). Assays were 
conducted in duplicate.  
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2.5.2. Combination chemotherapy studies 
Drug combination assays were carried out as described for single drug assays, with slight 
alterations. Three to 4 adult worms were transferred into each well of a 48-well plate 
containing 500 l pre-warmed supplemented RPMI medium. Then, 250 l of the drug solution 
#1 and 250 l of the drug solution #2 were added at a constant dose ratio based on the 
calculated IC50 values (inhibitory concentration 50%) and 2-fold dilutions were carried out up 
and down. In more detail, the following combinations were tested: 2IC50:2IC50 (for oxantel 
pamoate-pyrantel pamoate and oxantel pamoate-levamisole only), IC50:IC50, 0.5IC50:0.5IC50 
and 0.25IC50:0.25IC50. Since for albendazole, mebendazole and ivermectin no IC50 value 
could be calculated (IC50s > 200 µg/ml) [27] a concentration of 400 µg/ml was selected as 
IC50 value. A combination index (CI) was calculated to characterize the interaction of each 
combination: synergism (CI<1), antagonism (CI>1) and additive effect (CI=1) [19].  
 
2.6. In vitro studies with Ancylostoma ceylanicum and Necator americanus 
2.6.1. Oxantel monotherapy 
In vitro studies with A. ceylanicum and N. americanus third-stage larvae (L3) and adult 
worms were conducted as described recently [23]. Briefly, in a 96-well plate (Costar), 30 L3 
per well were incubated for 72 hours at room-temperature in 200 μl HBSS medium 
supplemented with 10% v/v amphotericin B (250 µg/ml, Sigma-Aldrich), 1% v/v penicillin-
streptomycin (10’000 U/ml penicillin + 10 mg/ml streptomycin, Sigma-Aldrich) containing 
oxantel pamoate dilutions ((0.1), 1, 10 and 100 µg/ml, final concentrations). The larval 
survival was determined microscopically (magnification 20x) following addition of hot water 
(~80°C) and exposure to microscope light. Two to 3 adult worms, collected from the 
hamsters intestines (binocular, magnification 16x) were incubated per well in 48-well plates 
for 72 hours in 1 ml supplemented HBSS medium and 10% v/v fetal calf serum containing 
oxantel pamoate dilutions (ranging from 0.1 to 100 µg/ml) at 37°C, 5% CO2. The motility was 
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determined microscopically (magnification 20x) using a viability scale ranging from 2 (normal 
viability, 100% motility) to 0 (death). Control worms were incubated with the highest DMSO 
concentration used in the test (2% v/v). Assays were conducted in triplicate.  
 
2.7. In vivo studies 
2.7.1. Trichuris muris  
Each animal was checked for the presence of eggs in the stools on day 40 p.i. and assigned 
to treatment or control groups (n=4 mice per group) and treated with a single oral drug dose 
on the following day. Oxantel pamoate was administered at 10 mg/kg, 5 mg/kg, 2.5 mg/kg 
and 1 mg/kg. Two groups of mice were treated intraperitoneally with 10 mg/kg oxantel 
pamoate and 10 mg/kg ivermectin. Expelled worms, recovered from stools collected for up to 
72 hours after treatment, were counted. At dissection, worms remaining in the gut 7 days 
post-treatment were collected and counted. Worm burden arithmetic means were calculated 
for each treatment and control group. Worm burden reductions (WBRs) and worm expulsion 
rates (WERs) were calculated as described previously [23, 27]. Drug combinations revealing 
synergism in vitro (CI<1) (oxantel pamoate-albendazole, oxantel pamoate-levamisole, 
oxantel pamoate-mebendazole and oxantel pamoate-ivermectin), were tested in vivo using a 
constant dose ratio. The ratio of the ED50s (effective dose 50%) of each drug was chosen as 
starting dose (ED50:ED50). If the treatment reduced the worm burden by more than 75% 
(threshold for additivity when the dose effect curves for both drugs are hyperbolic [19]), the 
drug doses were divided in half. ED50 values of the partner drugs were 345 mg/kg for 
albendazole, 79 mg/kg for mebendazole (both values determined in the frame of the present 
work), 4 mg/kg for ivermectin, and 46 mg/kg levamisole [22, 23].  
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2.7.2. Ancylostoma ceylanicum and Necator americanus 
The experiments were carried out as described recently [27]. Briefly, the fecal egg burden 
was established on days 21 and 22 p.i. (A. ceylanicum) and 46 and 47 (N. americanus) and 
treatment and control groups formed on the basis of arithmetic mean fecal egg burden. 
Hamsters were treated with a single oral dose of 10 mg/kg oxantel pamoate on the following 
day. Animals left untreated served as controls. Forty-eight hours after treatment, the 
complete stools were collected from each hamster and searched for expelled worms 
(binocular, magnification 16x). Worms remaining in the gut 7 days post-treatment were 
collected and counted after sacrificing the hamsters. The WERs were calculated. 
 
2.8. Statistical analyses 
All data obtained were analyzed by Excel (Microsoft Office, 2007). In vitro data obtained from 
the individual data with the motility assay were averaged and normalized to the controls. 
IC50s (median-effect dose), defined as the concentration of a drug required to decrease the 
mean worm’s motility to 50% at the 72 hour time point, were calculated with the CompuSyn 
software (CompuSyn, version 3.0.1). The combination index (CI) was calculated for the 
combination chemotherapy data with the CompuSyn software. To test the significance of the 
worm burden reductions in vivo, the Kruskal-Wallis (several treatment doses vs. controls) or 
the Mann-Whitney U-test (one treatment dose vs. control) was applied, using StatsDirect 
(version 2.4.5; StatsDirect Ltd; Cheshire, UK). 
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3. Results 
 
3.1. In vitro studies with T. muris 
3.1.1. Oxantel monotherapy 
Temporal drug effects of different oxantel pamoate concentrations over the incubation period 
of 72 hours are depicted in Figure 1. Exposure of T. muris to 0.15 and 0.3 µg/ml oxantel 
pamoate achieved only a negligible effect (mean motilities of 76.7% (±31.3%) and 83.3% 
(±23.3%) respectively) on the worms 24-72 hours post-treatment. Incubation of T. muris L4 
for 24-72 hours with 0.6-600 µg/ml oxantel pamoate resulted in strongly reduced viabilities 
within 24 hours but did not kill the worms. Control worms showed normal movements over 
the entire incubation period. We calculated an IC50 of 2.35 µg/ml for oxantel pamoate 
(corresponding to 0.78 µg/ml for the free base oxantel) on T. muris L4 (Table 1).  
 
3.1.2. Trichuris muris combination chemotherapy 
Oxantel pamoate was combined with albendazole, mebendazole, pyrantel pamoate, 
ivermectin or levamisole using ratios based on their IC50s and T. muris adults were exposed 
simultaneously to one of these combinations. The results are presented in Table 1 and dose 
response relationships of the combinations depicted in Figure 2. Synergistic effects were 
observed for four of the combinations, namely oxantel pamoate-mebendazole (CI=0.06), 
oxantel pamoate-ivermectin (CI=0.27), oxantel pamoate-albendazole (CI=0.37) and oxantel-
pamoate levamisole (CI=0.46). An antagonistic interaction was found when oxantel pamoate 
was combined with pyrantel pamoate (CI=2.53). Worms exposed to this combination were 
only affected at the 2 highest concentration ratios (2IC50:2IC50 and IC50:IC50) and showed 
normal viabilities at the 2 lowest concentration ratios examined (0.5IC50:0.5IC50 and 
0.25IC50:0.25IC50).  
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3.2. In vitro studies with Ancylostoma ceylanicum  
A. ceylanicum L3 incubated with oxantel pamoate revealed high survival rates (92.9% ± 
0.01% at 1 µg/ml, 100% ± 0.0% at 10 µg/ml and 95.3% ± 0.07% at 100 µg/ml), compared to 
controls. Similarly, adult worms were only weakly affected by the drug, showing an average 
motility of 100% (±0.0%) at 0.1 and 1 µg/ml and 83.5% (±29.0%) at 10 and 100 µg/ml 
compared to controls (motility of 100% (±0.0%)). 
 
3.3. In vitro studies with Necator americanus  
N. americanus L3 incubated with oxantel pamoate revealed high survival rates (100% ± 
0.05% at 0.1 µg/ml, 97.7% ± 0.04% at 1 µg/ml, 97.1% ± 0.003% at 10 µg/ml and 96.6% ± 
0.0% at 100 µg/ml), compared to controls. In contrast, adult worms were markedly affected 
by the drug, resulting in an average motility of 100% (±0.0%) at 0.1 µg/ml, 50% (±25.0%) at 1 
µg/ml and 62.5% (±40.5%) at 10 µg/ml and only 12.5% (±25.0%) at 100 µg/ml compared to 
controls (motility of 100% (±0.0%)). An IC50 of 11.80 (r=0.89) was calculated for N. 
americanus adult worms (Table 1). 
 
3.4. In vivo studies with Trichuris muris  
3.4.1. Oxantel monotherapy 
Oxantel pamoate displayed a high activity against T. muris in vivo, with an ED50 of 4.71 
mg/kg. In more detail, a worm burden reduction of 92.5% and worm expulsion rate of 88.4% 
was achieved after administration of 10 mg/kg (Table 2). Administration of 5 mg/kg resulted 
in a WBR of 81.1% and a WER of 78.2%. A moderate activity was observed with oxantel 
pamoate at 2.5 mg/kg (WER=24.1%, WBR=13.5%) and no effect was observed when mice 
were treated with 1 mg/kg (WER=1.5%, WBR=0%). The worm burden in orally oxantel 
pamoate treated mice was significantly different from untreated mice (P=0.041). An 
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intraperitoneal treatment of 10 mg/kg lacked activity against T. muris (both WER and 
WBR=0%). For comparison, 10 mg/kg ivermectin given intraperitoneally resulted in a worm 
burden reduction of 93.5%. 
 
3.4.2. Combination chemotherapy 
The 4 drug combinations that displayed synergistic effects in vitro were followed up in vivo 
(Table 2). Simultaneous treatment of T. muris-infected mice with a combination of oxantel 
pamoate and albendazole using the approximate ED50 doses resulted in a WBR of 76.6%, 
while combining 0.5ED50s was inefficacious (WBR=0%). The combination was modeled as 
antagonistic (CI=1.90). A synergistic interaction was found for the combination oxantel 
pamoate-mebendazole, as illustrated by a combination index of 0.15. A WBR of 88.8% was 
achieved combining both drugs using the ED50 doses and a still moderate WBR of 58.2% 
was observed when doses of 0.63 mg/kg oxantel pamoate and 10 mg/kg mebendazole (1/8 
ED50s) were administered. Oxantel pamoate combined with ivermectin achieved a WBR of 
84.8% at the highest dose tested (ED50:ED50 (5 and 4 mg/kg) of oxantel pamoate and 
ivermectin, respectively), but the combination at 0.5ED50: 0.5ED50 revealed a worm burden 
reduction of 37.5% only. The combination dose-effect analysis yielded antagonistic 
properties for the oxantel pamoate-ivermectin combination (CI=1.27). Similarly although the 
combination of oxantel pamoate and levamisole at the ED50:ED50 removed most of the worms 
(WBR=82.0%, WER=71.7%), using half of the dosage reduced the worm burden by less than 
50% (WBR=34.3%, WER=31.1%). The overall behavior of the combination of oxantel 
pamoate and levamisole was found to be antagonistic (CI=1.27). 
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3.5. In vivo studies with A. ceylanicum and N. americanus 
Oxantel pamoate exerted no effect on A. ceylanicum in vivo following a single dose treatment 
of 10 mg/kg, illustrated by a WER of 0% (data not shown). The same oral treatment (10 
mg/kg) in the N. americanus model resulted in a very low WER of 10.3% (data not shown). 
 
 
4. Discussion 
Since the introduction of albendazole, mebendazole, levamisole, and pyrantel pamoate in the 
human armamentarium to treat STH infections 3-4 decades ago, efforts to discover and 
develop a novel nematocidal drug have been scarce. The danger of resistance development 
therefore raises concern for the availability of therapy options in the future. Furthermore, all 
four above-mentioned drugs have a limited activity against Trichuris spp when administered 
as single oral doses. To spur the discovery of novel anthelminthic treatments potential drug 
candidates have recently been examined in vitro, in vivo and in clinical trials. Disappointingly, 
nitazoxanide, a potential drug candidate identified in systematic literature search [6] as well 
as a combination of albendazole and nitazoxanide revealed low trichuricidal activity in a 
randomized placebo controlled trial on Pemba [28]. Furthermore, monepantel, a safe 
nematocidal drug recently marketed in veterinary medicine showed a very low activity against 
Ascaris suum and T. muris in vitro and in vivo [23]. Hence, neither nitazoxanide nor 
monepantel can be recommended for the treatment of infections with STH.  
In the present work, another potential candidate, oxantel pamoate, widely used in veterinary 
medicine was evaluated against T. muris and hookworms in vitro and in vivo. Oxantel 
pamoate revealed an excellent trichuricidal activity in mice. We calculated an ED50 of 4.7 
mg/kg in T. muris-infected mice. A similarly low ED50 of 1.7 mg/kg was reported previously in 
this model [8]. For comparison, the WHO recommended drugs for the treatment of STH 
infections are characterized by much higher ED50 values in this model, namely 345 mg/kg for 
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albendazole, 79 mg/kg for mebendazole, 46 mg/kg for levamisole and > 300 mg/kg for 
pyrantel pamoate [23, 27]. Ivermectin, used in the treatment of strongyloidiasis and filarial 
infections, displayed a comparable ED50 value of 4 mg/kg in our T. muris model [29]. 
Interestingly, a dose of 10 mg/kg oxantel pamoate administered intraperitoneally lacked 
activity in T. muris-infected mice. For comparison, the same i.p. dose of ivermectin resulted in 
a high reduction of the worm load (>93%). This demonstrates that in contrast to ivermectin 
oxantel pamoate does not kill the worm via the blood stream, which might also be explained 
by the poor absorption of the drug in the gastrointestinal tract [13].  
Oxantel pamoate lacked in vivo activity against both hookworm species A. ceylanicum and N. 
americanus. This finding is in line with a previous study in A. caninum-infected mice [30]. 
Interestingly, N. americanus adults were affected by the drug in vitro while no activity was 
observed on A. ceylanicum. To our knowledge, the activity of oxantel pamoate against 
hookworms has not been studied in humans.  
Oxantel pamoate showed also no effect against the third major soil-transmitted helminth 
species, A. lumbricoides in humans (all 53 patients treated with oxantel revealed Ascaris 
eggs in the stools collected post-treatment regardless of the dose administered) [9]. It is 
therefore necessary to combine oxantel pamoate with a partner drug, which therapeutic 
profile covers roundworms and hookworms. In the present work we have for the first time 
thoroughly evaluated the potential of oxantel pamoate in drug combinations. Interestingly, 
antagonistic effects were observed with oxantel pamoate-pyrantel pamoate against T. muris 
in vitro, hence this combination was not pursued further. However, we cannot exclude a 
better trichuricidal effect in vivo for this combination, in particular as a pharmacodynamic 
interference at the target is unlikely. Oxantel is classified as an N-subtype AChR agonist, 
while pyrantel is considered an L-subtype suggesting differences in drug action [31]. The 
combination of oxantel pamoate-pyrantel pamoate is widely used in veterinary medicine and 
has also been studied in several human clinical trials. For example, in Korea oxantel 
pamoate-pyrantel pamoate at 20 mg/kg achieved a cure rate of 75% and egg reduction rate 
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of 97% against T. trichiura infections and cleared A. lumbricoides infections [11]. A high egg 
reduction rate against T. trichiura following oxantel pamoate-pyrantel pamoate at 20 mg/kg 
was also reported in a Malaysian study [16]. A lower effect of this combination administered 
at 10 mg/kg was observed on Pemba with cure rates of 96.3, 38.2 and 12.7% against A. 
lumbricoides, T. trichiura and hookworm, respectively [17]. In 2 Korean trials both oxantel 
monotherapy as well as an oxantel-pyrantel combination were used, however since different 
formulations were used (syrup versus tablets), different dosages applied and sample sizes 
were small no conclusion can be drawn whether the combination was superior to oxantel 
monotherapy [11,12].  
Antagonistic effects were observed in vivo using combinations of oxantel pamoate-
albendazole, oxantel pamoate-levamisole and oxantel pamoate-ivermectin. Since the 
molecular basis of actions of these drugs is not yet fully elucidated it is impossible to explain 
the antagonistic interaction profile observed for these combinations. In addition, drug 
scheduling, host behavior, environmental factors and genetic variations might also influence 
the level of activity [32]. Furthermore, note that these findings are based on a single ratio of 
the combined agents (ED50 values) and it might be worthwhile to assess other ratios of the 
drug dosages in particular for the combination of oxantel pamoate-albendazole, since of the 
standard drugs albendazole has the highest efficacy against hookworms [5]. On the other 
hand, the oxantel pamoate-mebendazole combination revealed highly synergistic effects 
against T. muris in vivo. Why the two benzimidazole derivates behave so differently when 
administered as partner drugs in oxantel pamoate combinations cannot be explained at the 
moment, but differences in their pharmacokinetic properties [33] might play a role.  
In conclusion, our studies confirm that oxantel pamoate has excellent trichuricidal properties. 
In the T. muris mouse model oxantel pamoate showed a higher activity than the standard 
drugs albendazole, mebendazole, levamisole and pyrantel pamoate. Since the drug has no 
activity against hookworms it is necessary to combine oxantel pamoate with a partner drug 
revealing anti-hookworm properties. Synergistic effects were observed for oxantel pamoate-
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mebendazole. Despite of our results pointing to an antagonistic behavior of oxantel pamoate-
albendazole additional investigations on the combination effect of these agents should be 
launched (e.g. evaluation of a different dosing ratio or schedule) since of the standard drugs 
albendazole has the highest efficacy against hookworms. Systemic drug interactions 
between oxantel pamoate and partner drugs are most likely not to be expected given that, as 
mentioned, the absorption of oxantel pamoate is very poor. Nonetheless, preclinical studies 
should carefully elucidate metabolic and pharmacokinetic interactions of oxantel pamoate 
and the benzimidazoles.  
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Table 1: In vitro activity of oxantel pamoate against T. muris, A. ceylanicum and N. americanus.  
 
 
 
 
 
 
 
 
 
 
IC50 median effect dose. r = linear correlation coefficient of the median-effect plot, indicating the goodness of fit. r ≥ 0.85 indicates a satisfactory fit. 
IC50s of albendazole, mebendazole, levamisole, pyrantel pamoate, and ivermectin have been published elsewhere [23]. n.d. = not determined. 
Drugs  IC50 (r) 
T. muris L4 A. ceylanicum N. americanus 
 IC50 (r) 
Combination 
index (CI) at 
IC50 
L3 Adults L3 Adults 
Oxantel 2.35 (0.68) - > 100 (n.d.) > 100 (n.d.) > 100 (n.d.) 11.80 (0.89) 
Oxantel-Albendazole 159.61 (0.87) 0.37 - - - - 
Oxantel-Mebendazole 27.95 (0.87) 0.06 - - - - 
Oxantel-Levamisole 2.93 (0.99) 0.46 - - - - 
Oxantel-pyrantel pamoate 67.13 (0.90) 2.53 - - - - 
Oxantel-Ivermectin 116.86 (0.94) 0.27 - - - - 
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Table 2: Activity of oxantel pamoate monotherapy or combination chemotherapy 
against T. muris in vivo. 
 
Numbers in superscript refer to the corresponding control group. aP-values were obtained 
from the Kruskal-Wallis test (several treatment doses vs. controls), bP-values were obtained 
from the Mann-Whitney U test (one treatment dose vs. controls). The CI at IC50 are based on 
WBR.
Group Dose 
(mg/kg) 
Mean 
number  
of worms 
(SD) 
Mean 
number  
of expelled 
worms (SD) 
Worm 
expulsion rate 
(%) 
Worm burden 
reduction (%) 
P-
value 
Combination 
index (CI) 
Control 1 – 157.5 (62.6) 0.2 (0.5) 0.1 – – – 
Control 2 – 93.3 (9.5) 0.8 (1.0) 0.8 – – – 
Control 3 – 109.5 (32.9) 0.8 (0.5) 0.7 – – – 
Control 8 – 56.5 (22.1) 0 (0) 0 – – – 
Oxantel pamoate 
101 91.7 (46.1) 81.0 (44.0) 88.4 92.5 
0.041a – 
52 80.3 (40.0) 62.8 (37.5) 78.2 81.1 
2.52 105.7 (58.5) 25.7 (16.0) 24.3 13.51 
12 148.3 (94.1) 2.3 (2.1) 1.5 0 
Albendazole 
3003 69.0 (63.7) 5.8 (4.5) 8.3 41.8 
0.293a – 
751 139.0 (54.9) 0.5 (1.0) 0.4 2.6 
Mebendazole 
1502 99.8 (47.8) 70.3 (36.1) 70.4 68.1 
0.006a – 
751 115.8 (36.5) 42.7 (18.6) 36.5 48.3 
Oxantel pamoate 108 i.p. 44.0 (18.7) 0 (0) 0 0 0.857b – 
Ivermectin 108 i.p. 80.7 (59.5) 77 (62.0) 95.5 93.5 0.057b – 
Control 4 – 123.3 (35.1) 0.3 (0.5) 0.2 – – – 
Control 5 – 91.3 (23.7) 0 (0) 0 – – – 
Control 6 – 78.3 (20.8) 0 (0) 0 – – – 
Control 7 – 94.4 (39.2) 0 (0) 0 – – – 
Control 8 – 56.5 (22.1) 0 (0) 0 – – – 
Oxantel pamoate- 
albendazole 
5+3454 105.0 (80.1) 76.3 (80.5) 72.6 76.6 
0.529a 1.90 
2.5+172.58 191.0 (123.4) 44.5 (45.4) 23.3 0 
Oxantel pamoate- 
mebendazole 
5+794 101.3 (39.8) 87.5 (27.6) 86.4 88.8 
<0.001a 0.15 
2.5+39.54 53.0 (27.8) 41.3 (28.6) 77.8 90.5 
1.25+19.755 128.8 (68.8) 107.5 (69.3) 83.5 76.7 
0.63+106 106.8 (49.9) 74.0 (42.7) 69.3 58.2 
Oxantel pamoate- 
ivermectin 
5+44 79.0 (20.8) 60.3 (14.5) 76.3 84.7 
0.008a 1.27 
2.5+25 116.7 (28.3) 59.7 (15.9) 51.1 37.5 
Oxantel pamoate- 
levamisole 
5+467 60.0 (40.2) 43.0 (30.5) 71.7 82.0 
0.028a 1.27 
2.5+237 90.0 (45.6) 28.0 (19.4) 31.1 34.3 
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Abstract  
Background: The prevalence of hookworm disease caused by Ancylostoma duodenale and 
Necator americanus and Plasmodium falciparum-induced malaria shows a large geographic 
overlap, in particular in sub-Saharan Africa. Robust, accurate, and highly sensitive diagnostic 
tools are required to detect even low parasitic burdens in both diseases, especially in low-
transmission settings.  
Methods: Murine hookworm (Heligmosomoides bakeri) and malaria (Plasmodium berghei) 
single and co-infection models (delayed and simultaneous) were established in NMRI 
outbred mice to study infection-related metabolic responses. Urine and plasma samples were 
collected from every mouse at 6 key time points over the course of the infection. The 
samples were analyzed using 1H NMR spectroscopy and subsequent multi- and univariate 
statistical approaches, in order to reveal and identify differences between the infection 
groups, and to establish time trajectories within each infection. Identified candidate 
biomarkers were documented and related to the parasitological and physiological measures 
of the rodent models. 
Findings and conclusion: A characteristic metabolic fingerprint has been found for each of 
the five infection scenarios assessed. Pipecolic acid, which has been identified previously as 
biomarker for P. berghei single infection has shown here to be not only specific to all P. 
berghei exposed groups but the compound remained to be present in significantly higher 
levels than in P. berghei unexposed groups, even in co-infection with a nematode worm. 
Pipecolic acid may hence represent a promising candidate for human malaria diagnostics 
and will be further validated.  
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1. Introduction 
In 2010, Plasmodium-induced malaria accounted globally for about 216 million cases and 
more than 600,000 deaths mostly amongst children in sub-Saharan Africa. P. falciparum is 
the most deadly species, inflicting the greatest annual mortality burden of all parasitic 
diseases (WHO 2011). The two nematode worms Necator americanus and Ancylostoma 
duodenale, on the other hand, are the causative agents of hookworm disease, which 
represents the most frequent chronic tropical infection affecting an estimated 576-740 million 
people, whereby about 5 billion people are at risk worldwide (de Silva, Brooker et al. 2003; 
Bethony, Brooker et al. 2006; Pullan and Brooker 2012). One quarter of all school-aged 
children on the African continent (~45 million) are likely to harbor concomitant infections with 
Plasmodium falciparum malaria and a hookworm species at any given time (Brooker, 
Clements et al. 2006) due to the large geographical overlap of the parasite incidence. By 
affecting mostly the poor, each disease contributes to an entrenched cycle of ill-health, 
missing education in children, and declined work performance of affected adults. The burden 
of a co- or poly-infection, which represents the more common scenario in resource-poor 
settings, is often even more debilitating. Besides a frequently observed increase in anaemia 
caused by the co-existence of both parasites in the same host (Brooker, Akhwale et al. 
2007), controversial reports exist on the interactions between Plasmodium and the 
nematodes in humans. Whereas hookworm infections were associated with P. falciparum-
induced malaria in some field studies (Hillier, Booth et al. 2008; Midzi, Sangweme et al. 
2008; Nacher 2011), no association was discovered by Shapiro and colleagues (Shapiro, 
Tukahebwa et al. 2005). Degarege and colleagues recently studied the nature of interaction 
between hookworms and P. falciparum malaria and found that light hookworm infections tend 
to decrease malaria parasitaemia, but a trend for heavy hookworm infections to increase the 
malaria parasitaemia (Degarege, Animut et al. 2009). Despite sometimes inconsistent 
findings, the overall trend shows a worsened malaria pathogenesis if a concomitant 
hookworm infection is present (Adegnika and Kremsner 2012). However, so far, little 
attention has been given to the hookworm-malaria interactions in the human host.  
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At present, the gold standard to diagnose any Plasmodium infection relies on microscopy. 
This is the only method to accurately quantify malaria parasite density, but the approach is 
time-consuming, prone to individual subjectivity and relies on blood samples obtained by 
finger prick (O'Meara, McKenzie et al. 2005; malERA 2011). Hookworm infections are 
detected by copromicroscopic methods, based on microscopical detection of helminth eggs 
in faecal material, whereby sensitivity is sub-optimal, and does not relate to the intensity of 
infection. Light and early infections may easily be missed, and multiple stool samples are 
often required (Knopp, Mgeni et al. 2008; Glinz, Silue et al. 2010). PCR-based techniques 
and antigen-based assays are often presented as alternative means for detection of many 
parasitic diseases (Knopp, Mohammed et al. 2010; Taniuchi, Verweij et al. 2011). However, 
although they may offer improved sensitivity and/or specificity, they present major 
drawbacks, including potential cross-reactivity, cost, high detection thresholds, the necessity 
of a laboratory off field, technology and substantial expertise (Neppert 1974; Bergquist, 
Johansen et al. 2009; malERA 2011). 
Diagnostic means for detection of multiple infections at the same time (multiplexing) and 
application for large scale screenings in the field are strongly desirable. Ideally, diagnostic 
would be based on a sample matrix that can be obtained in a non-invasive way (e.g. urine or 
saliva). Such a tool would indeed greatly facilitate integrated control programs for multiple 
parasitic species. 
Metabolic profiling has broadly been used to gain knowledge about host-parasite 
interactions, and to discover infection-related diagnostic markers. However, the approach 
has been substantially developed since the initial screening of urine samples for 
Schistosoma mansoni-infected mice and their uninfected counterparts. Eleven single 
infection rodent models have been reported so far, whereby each of them showed an 
infection-specific fingerprint in urine and/or plasma, our most commonly characterized 
biological matrices in the rodent (Li, Wang et al. 2008; Saric, Li et al. 2009; Wang, Xiao et al. 
2009). Although efforts have been made recently for describing metabolic effects in humans 
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(Denery, Nunes et al. 2010; Balog, Meissner et al. 2011), the biggest challenge in human 
biomarker discovery remains the high prevalence of co- and multiple infections in low income 
countries. In order to predict the metabolic fingerprint of a co- or poly-infection it is necessary 
to gain more understanding on the effect of parasite co-existence to the host metabolism.  
The goal of the present work was to investigate the metabolic effects of a malaria-hookworm 
co-infection in the murine host in a laboratory-controlled experiment, and to identify candidate 
biomarkers that overlap between single and each co-infection. Mice underwent either single-
infection with P. berghei or the mouse hookworm Heligmosomoides bakeri, co-infection with 
both parasites in a simultaneous or delayed manner, or they remained uninfected and served 
as control group. Plasma and urine samples were collected one day pre-infection and five 
times during the course of infection in order to capture acute and chronic effects and 
evaluate the consistency of the candidate metabolic markers over both phases. Samples 
were acquired by 1H nuclear magnetic resonance (NMR) spectroscopy and analyzed using 
multivariate and univariate statistical approaches.  
 
 
2. Materials and methods 
2.1. Animals and parasites 
Forty 3-week-old female NMRI mice were purchased from Charles River (Sulzfeld, Germany) 
and kept in groups of 8 in macrolon cages under standard environmentally-controlled 
conditions (temperature: 25°C, humidity: 70%, light/dark cycle 12/12 h). Mice had access to 
water and rodent food ad libitum (Rodent Blox from Eberle NAFAG, Gossau, Switzerland) 
and were allowed to acclimatize in the animal facility of the Swiss Tropical and Public Health 
Institute (Swiss TPH) for one week before the first sampling was conducted. The current work 
was approved by the local and national regulations of laboratory animal welfare (permission 
no. 2081). Mice were tagged 2 days prior to infection. 
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2.2. Study design 
Each group of 8 mice was allocated to a different infection schedule (See Figure 1). On day 
0, groups H and CD received 80 infective H. bakeri L3 larvae which were administered orally 
in 150 µl water. Details on the life cycle of H. bakeri, maintained at the institute since 2009 
have recently been described (Nwosu, Vargas et al. 2011).  
Three groups of mice received 2 x 107 erythrocytes, parasitized with the GFP-transfected P. 
berghei ANKA strain in 0.2 ml intravenously (Franke-Fayard, Trueman et al. 2004), on day 
15, resulting in P. berghei single infection (Group P), delayed co-infection (Group CD) and 
simultaneous co-infection (Group CS), whereby the latter received additionally H. bakeri at 
the same time. Group C remained uninfected and served as control. All mice were sacrificed 
by spinal dislocation on day 19.  
 
2.3. Biofluid collection, weight and PCV determination 
Urine and blood were collected one day before infection and 1, 8, 14, 16 and 19 days after 
experiment start (day 0), always between 8 and 11 AM (Figure 1). 
Mice were individually placed into empty cages and monitored until they released a minimum 
of 40 µl urine which was immediately collected into 1.5 ml Eppendorf tubes and frozen over 
dry ice. All samples were stored at -80°C prior to 1H NMR acquisition. 
Approximately 50 µl tail blood was sampled from each mouse into a Na-heparinized 
hematocrit tube (1.55 mm Ø, BRAND GMBH + CO KG; Wertheim, Germany) and centrifuged 
at 11,000 x rpm for 5 minutes (microcentrifuge Sigma 1-15). The ratio of plasma to red blood 
cells was determined by measuring packed cell volume (PCV) and the whole blood volume 
(in mm). The plasma fraction was transferred into 1.5 ml Eppendorf tubes and stored at -
80°C. On day 19, a heart puncture was performed after euthanasia of the animals by spinal 
dislocation. On each sampling day, mice were monitored for weight, to the nearest 0.05 g.  
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For weight and PCV, intergroup median variation was analyzed using the Mann-Whitney U 
test with Bonferroni correction in StatsDirect (version 2.4.5; StatsDirect Ltd; Cheshire, UK), 
with a significance level of 5%.  
 
2.4. Worm burden and parasitemia 
The worm burden was determined upon dissection of the intestine and manual counting of 
adult worms, whereas the parasitemia in the P. berghei infections was evaluated by FACS 
analysis (FACScan, Becton Dickinson, Basel, Switzerland) on day 19, by counting 100,000 
erythrocytes (Franke-Fayard, Trueman et al. 2004). The worm burden in groups H and CD 
was compared using the Mann-Whitney U test (StatsDirect). Eventual intergroup variation in 
median blood parasitemia was evaluated using the Mann-Whitney U test with Bonferroni 
correction.   
 
2.5. Sample preparation and 1H NMR spectroscopic analysis 
All samples were sent to Imperial College London on dry ice for 1H NMR-based analysis. 
Urine samples were prepared by mixing 30 µl phosphate buffer (43.8 mM NaH2PO4 and ≈ 0.2 
M Na2HPO4, 70% D2O v/v, 0.1% sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 pH = 7.4) with 
30 µl urine and centrifuged 5 minutes at 13,000 rpm (microcentrifuge Sigma 1-14). Fifty-five 
µl of the sample were transferred into NMR microtubes (Bruker, 1.7 mm Ø), and stored at 
4°C prior to data acquisition. 
Plasma samples were prepared by mixing 25 µl plasma with 30 µl NaCl buffer (0.9 % NaCl, 
10% D2O v/v, pH = 7.4) in Eppendorf tubes and centrifuged 5 minutes at 13,000 rpm. A 
volume of 50 µl was transferred into NMR microtubes (Bruker, 1.7 mm Ø) shortly before 
measurement, and stored at 4°C prior to spectral acquisition. 
 Chapter 7 
130 
 
A standard 1H NMR spectrum was acquired from each individual sample on a Bruker 600 
DRX MHz spectrometer (Rheinstetten, Germany), in a one-dimensional (1D) NOESY 
(nuclear overhauser effect spectroscopy) experiment, using the standard solvent suppression 
pulse delay [recycle delay (RD)-90°-tl-90°-tm-90°-acquire free induction decay (FID)] 
(Nicholson, Foxall et al. 1995). A constant temperature of 300 K was maintained during 
spectral acquisition. For plasma samples, a second set of data was acquired, using a 1D 
Carr-Purcell-Meiboom-Gill (CPMG) pulse [RD-90°-(τ-180°-τ)n] sequence (Meiboom 1958). 
The samples were scanned 256 times in each experiment.  
 
2.6. Data reduction, multivariate analysis and metabolic trajectories 
All 1H NMR spectra were manually phased and baseline-corrected in Topspin (Version 3.1, 
Bruker). Plasma spectra were referenced to lactate at δ 1.33, whereas urine samples were 
adjusted to the TSP peak at δ 0.00. The complete spectra from δ 0.5-9 were imported into 
MATLAB (Version 7.12.0, R2011a) and the water peak region was removed in all spectra (δ 
4.18-5.77). Since signals from ethanol and methanol were detected in plasma which may 
represent potential contaminations, the corresponding spectral regions (δ 1.15-1.22, 3.64-
3.69 and 3.355-3.375, in plasma NOESY spectra) were additionally removed to not bias the 
data modeling process. Spectral pre-processing further included median-fold normalization 
and peak alignment using in-house developed scripts (Veselkov, Vingara et al. 2011).  
In plasma spectra, only the aliphatic region was included in the multivariate modeling in order 
to minimize the impact of the water related baseline distortion and to facilitate preprocessing 
of the whole data set, in particular the process of phasing and baseline alignment (δ 0.5-4.6). 
However, the group discriminatory power of formate, which was the only peak found between 
the water peak region and δ 9 was tested with the Mann-Whitney U test (StatsDirect).  
Orthogonal projection to latent structure discriminant analysis (O-PLS-DA) (Trygg and Wold 
2002; Cloarec, Dumas et al. 2005) was applied to compare 1H NMR spectral data between 
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the different murine infection groups and identify the discriminating compounds (biomarkers). 
Metabolic trajectories based on principal components analysis (PCA) were constructed for 
urine as well as for both plasma data sets (NOESY and CPMG). The mean position in the 
principal component (PC) scores plot was therefore taken for each infection group and at 
each time point separately, as described before (Saric, Li et al. 2008). In a next step, the 
coordinates were connected chronologically to establish any systematic change in the global 
metabolic composition over time, expressed by the 6 sampling days (Figure 4).  
.  
2.7. Metabolite Identification 
Metabolite identity was determined using the literature (Bell, Brown et al. 1987; Nicholson, 
Foxall et al. 1995; Liu, Nicholson et al. 1997; Coen, Lenz et al. 2003; Tang, Wang et al. 2004; 
Li, Wang et al. 2008), statistical total correlation spectroscopy (STOCSY) (Cloarec, Dumas et 
al. 2005), and the software Chenomx Profiler (Chenomx NMR Suite, 7.1, evaluation version). 
Assignments in urine were additionally confirmed with two-dimensional (2D) 1H-1H correlation 
spectroscopy (COSY), with the parameters described previously (Bax and Davis 1985; Hurd 
1990). 
One sample with high relative signals between 2.0-2.1 ppm was selected for conducting an 
enzymatic digestion with β-galactosidase (Jack Bean, Sigma) in order to confirm the nature 
of the glycoprotein. A baseline sample was therefore acquired and compared to the sample 
immediately after addition of 0.5 U of the enzyme (Bell, Brown et al. 1987) and during the 
next 20 h window. The assay was run on a 400 MHz spectrometer at an ambient 
temperature of 300 K and at a pH of ~ 7.4. The enzyme addition resulted in cleaving off of 
the acetyl group resulting in a marked increase of acetate and a subsequent decrease of the 
2.04 signal proving signal contribution from an N-acetyl glycoprotein, whereby α1-acid 
glycoprotein is likely to be the main contributor. 
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2.8. Validation of the candidate biomarkers 
Candidate biomarkers identified in O-PLS-DA (p < 0.05) were further validated by univariate 
analysis. The area under the curve (AUC) was extracted from the clearest signal for each 
metabolite found significant via O-PLS-DA analysis. Variance analysis between the mean 
values of the groups was performed using a Mann-Whitney U test with Bonferroni correction, 
with a significance level of 5%. Peaks that were found to be statistically insignificant 
according to the univariate analysis (Mann-Whitney U test) were removed unless they 
belonged to top 5 correlation coefficients extracted by multivariate (O-PLS-DA) analysis. All 
identified peaks that showed significance in both analysis sets were documented (Tables 1 
and 2).  
 
 
3. Results 
3.1. Parasitology 
Average worm counts of 42.38 (+/- 17.69) and 61.88 (+/- 18.37) were found in groups H and 
CD, respectively, but the difference was not statistically significant (p = 0.0531). The worm 
burden could not be established in the simultaneous co-infection, since larvae were too small 
and embedded in the intestinal mucosa. 
Blood parasitemia of 39.5%, 35.3% and 37.1% were determined for the groups P, CD and 
CS, respectively. They did not significantly differ in any of the pairwise comparisons between 
the 3 P. berghei-infected groups.  
 
3.2. Weight and PCV 
No significant weight variation could be identified between groups at any of the time points 
assessed. PCV values, on the other hand, were found significantly lower in group P 
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compared to group H (p = 0.012), and group CS respectively (p = 0.019) one day before 
infection. However, this was no longer the case on day 1 post infection. On day 16 only, the 
mean PCV was found lower in group P than in group CD (p = 0.04). On day 19, mice with a 
P. berghei single infection presented a significantly lower average PCV value (37.68%) 
compared to animals harboring a H. bakeri single infection or control mice (52.60% and 
51.90%, p = 0.003 and 0.006, respectively). Delayed and simultaneously co-infected mice 
presented the same feature over helminth-infected or control mice, with average PCV values 
of 28.46% and 34.29% (all p ≤ 0.003). Mean PCV values did not vary significantly between 
both co-infection groups, nor between P. berghei-infected mice and both co-infection groups. 
Infection with H. bakeri alone did not lead to a decreased PCV compared to the uninfected 
group.  
 
3.3. Urine and plasma 1H NMR spectral profiles of H. bakeri, P. berghei single and co-
infected mice 
Figure 2 depicts representative 600 MHz 1H NMR mouse urine spectra from P. berghei single 
infection (A), the delayed co-infection (B), and a H. bakeri single infection (C) on day 19. 
Urine spectra were characterized by the presence of 3-oxoisovalerate, 2-oxoisocaproate, 
creatine, hippurate, and formate, and a variety of amino acids, such as leucine and alanine. 
Two unknown metabolites (UK 1: d 1.21; d 1.24 and UK 2: t 6.05; d 6.3; d 7.4) were present 
in both the P. berghei infection and in the delayed co-infection (number 16 and 17, Table 1), 
but not the single H. bakeri infection. P. berghei-infected groups presented also elevated 
levels of 2-oxoisocaproate, trimethylamine and pipecolic acid. Infection with H. bakeri (single 
and delayed co-infection) was mostly characterized by elevated hippurate levels. Figure 3 
shows the typical spectral profile of a delayed co-infection plasma sample (NOESY, day 19). 
Plasma spectra showed the presence of several lipids, amino acids (leucine, isoleucine, 
valine, alanine and glycine), lactate, choline species as well as glucose. In P. berghei 
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infections (both single and delayed co-infections), an accumulation of lactate was typically 
observed, whereas increased glucose levels were noticed in H. bakeri-infected groups.  
 
3.4. Multivariate data analysis 
All infection groups were pairwise compared with each other, at all time points separately 
using O-PLS-DA within each urine and plasma data set. Candidate metabolic markers that 
have been found to be discriminatory between two given infection groups are presented in 
detail in Tables 1 and 2 (days 16 and 19 post infection, respectively). In brief, on day 16, 
urine samples indicated few metabolic changes (Table 1) including decreased hippurate 
levels in the H. bakeri single infection compared to uninfected controls and the delayed co-
infection, and increase in acetate in the simultaneous co-infection compared to controls. 
However, on day 19, a significant increase in pipecolic acid was detected in P. berghei-
infected animals compared to the H. bakeri single infection and the control group, whereby 
the delayed co-infection additionally revealed relatively higher levels than the P. berghei 
mono-infection. An accumulation in the unknown metabolites UK 1 and UK 2 (d 1.21; d 1.24 
and t 6.05; d 6.3; d 7.4; d 7.56) was furthermore observed in all P. berghei-infected groups 
on days 16 and 19. Succinate on the other hand showed depletion upon P. berghei exposure 
as revealed by comparison between all P. berghei positive groups and the uninfected control 
group. On day 19, an increase in 2-oxoisocaproate appeared in the P. berghei mono-
infection group and the simultaneous co-infected animals compared to all other groups. 
Increases in creatine and 2-oxoisovalerate characterized the simultaneous co-infection, 
however, not significantly when compared to the delayed co-infection. An increase in acetate 
was observed in the delayed co-infection compared to the P. berghei single infection. 
 
Plasma spectra obtained by CPMG and NOESY pulse programs revealed a greater amount 
of information whereby the trends were more pronounced on day 19 (Table 2). On day 16, 
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glucose was found decreased in P. berghei mono-infected animals compared to all other 
groups. Interestingly, this association became insignificant on day 19. In the simultaneous 
co-infection model the same trend was confirmed, i.e. lower glucose levels in presence of 
Plasmodium, on day 19 only. Consequently on day 19, a significant increase in lactate was 
observed in every P. berghei-infected group, without significant difference between them.  
Observed on day 16 only, a decreased level in the amino acid lysine characterized the P. 
berghei infections in single and delayed co-infection, whereas relatively increased levels 
were found in the H. bakeri mono-infection and the simultaneous co-infection, when 
compared to uninfected controls. Other amino acids such as leucine, valine and alanine were 
found augmented in P. berghei single and co-infections when compared to uninfected 
controls. On day 16, a decrease in glycerophosphocholine (GPC) was observed in P. 
berghei-infected animals and in the H. bakeri single infection group compared to uninfected 
controls. The same trend was still present but appeared less pronounced on day 19. The lipid 
metabolism was markedly affected on day 19, with a trend of accumulation of several lipid 
fractions in P. berghei single and co-infections. Pyruvate (tentatively assessed) characterized 
the simultaneous co-infection versus the H. bakeri-infected group and uninfected animals.  
 
3.5. Time trajectory analysis 
Metabolic time trajectories of each infection group are represented in Figure 4, based on 
spectra derived from urine (A), plasma acquired via NOESY (B) and plasma acquired 
applying a CPMG pulse program (C). Stars of the same color indicate significant differences 
between time points. The plasma CPMG data set revealed a general fundamental difference 
of day 14 compared to other time points in the uninfected control (C5) and simultaneous co-
infection (C4) groups (where no infection was induced before day 15). In plasma samples, a 
general metabolic impact inflicted by P. berghei infections was observed between day 14 or 
16 and day 19, reflecting the quick evolution of the infection, especially in the mono-infection 
and simultaneous co-infections. In both urine and plasma, H. bakeri infection was 
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characterized by significant movements between the early time points (day -1 and 1) and late 
time points (day 14 onwards). No significant movement was noted between all time points for 
P. berghei single infection in urine (A1) for the uninfected controls in plasma using the 
NOESY pulse program (B5) and for the H. bakeri single infection in plasma using the CPMG 
pulse program (C2). The uninfected control group showed the largest amount of significant 
changes in urine (A5), as well as the P. berghei single infection in plasma CPMG (A1).  
 
 
4. Discussion 
We have, for the first time, established a co-infection model of murine malaria and hookworm 
disease to study the impact of concurrent infections on the host metabolism. The 6 sampling 
time points were strategically set one day before and after each infection day. The H. bakeri 
infection is considered established after 14 days, when adult worms are present in the gut, 
whereas the evolution of P. berghei infections in NMRI mice is very quick (mice start dying 
from 5 days post-infection). The experiment was therefore terminated 4 days after exposure 
to the malaria parasite i.e. on day 19 of the experiment. Days 16 and 19 revealed the most 
information regarding metabolic changes. Pairwise comparison of each infection scenario 
with the uninfected control group revealed that the P. berghei-infected mice (single as well as 
co-infected groups) induced most metabolic changes in the rodent host. As shown by the 
time trajectories (Figure 4), most of the overall metabolic changes in the H. bakeri single 
infection group occurred on day 19, compared to the first 2 sampling time points, which may 
be reflective of the slow and chronic progress of the disease. In plasma from P. berghei-
infected animals perturbed metabolic profiles were observed after infection (on day 15) 
compared to the early sampling time points, but also between day 16 and day 19, reflecting 
the rapid development of the malaria infection. More biomarkers were found in urine on day 
19 than on day 16, whereby on day 19, elevated levels of pipecolic acid were detected in all 
P. berghei-infected groups, as reported earlier (Li, Wang et al. 2008). The compound can 
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accumulate due to a number of consequences of malaria infection such as liver dysfunction, 
disturbance of the gut microbiota, and neurological damage (Li, Wang et al. 2008). Pipecolic 
acid has also been described in human P. vivax infections and may represent a unique 
biomarker for Plasmodium (Sengupta, Ghosh et al. 2011). Pipecolic acid is therefore of great 
interest regarding diagnostics of Plasmodium spp.  
The depletion of plasma glucose was one of the main findings in the P. berghei single 
infection group on day 16, while this effect appeared with delay in the simultaneous co-
infection group, on day 19. As already discussed in detail by Li and colleagues (Li, Wang et 
al. 2008), Plasmodium-infected erythrocytes consume higher amounts of glucose than 
normal, as the parasites rely on anaerobic glycolysis (combined to reductive and oxidative 
Krebs cycle pathways) to obtain energy. Consequently, prominent lactate peaks appeared on 
day 19, in all P. berghei-infected groups. This is consistent with the exacerbated glucose 
consumption observed, since lactate is a waste product of the anaerobic glycolysis. In severe 
P. falciparum malaria, lactate is a death predictor, which accumulation can lead to cardiac 
impairment (Agbenyega, Angus et al. 2000).  
In a previous N. americanus hamster model, blood sugars tended to be higher than in 
uninfected controls (Kaul, Talwalker et al. 1982). Malabsorption of sugars has been 
demonstrated in hookworm-infected patients (Falaiye, Oladapo et al. 1974). However, the 
concentration of blood glucose was found decreased in a N. americanus hamster model for 
metabolic profiling (Wang, Xiao et al. 2009). Here, we used an NMRI mouse background and 
another hookworm species. Our results suggest that an established H. bakeri-infection 
compensates at least in part the P. berghei-induced plasma glucose depletion. In the 
simultaneous co-infection, the presence of hookworm larvae delayed glucose depletion. A 
significant increase in glucose level was observed in H. bakeri-infected animals compared to 
uninfected controls at the experimental day 8.  
Plasma GPC decreased in all P. berghei single and co-infections compared to the mouse 
groups absent of the protozoan parasite, a finding that is in accordance with the results of Li 
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and colleagues (Li, Wang et al. 2008). This effect 
was in the current experiment more pronounced on 
day 16 than on day 19. The breakdown of GPC into 
choline has been shown necessary for uptake by the 
infected erythrocyte and transformation to 
phosphatidylcholine, the most abundant membrane 
phospholipid in P. falciparum (Ancelin and Vial 1986; 
Lehane, Saliba et al. 2004; Dechamps, Maynadier et 
al. 2010).  
Since the delayed co-infection is reflective of the 
usual “real-life” scenario, i.e. underlying chronic 
helminth infection and occasional episodes of malaria, the main goal here was to identify 
valuable discriminators between each single infection and this particular co-infection 
scenario. The consequent overlap between metabolic profiles of these two diseases allowed 
isolating 3 metabolites from urine, namely pipecolic acid and the 2 unknowns UK 1 and UK 2 
which were related to the presence of P. berghei. For the hookworm single infection, a 
decrease in hippurate could be identified in urine on day 16. In plasma, increases in lactate 
and decreases in GPC were the most consistent changes following P. berghei infection. 
However, an accumulation of GPC was also observed in relation to the H. bakeri infection 
and therefore, should not be selected as candidate diagnostic biomarker. In the same way, 
the glucose metabolism was perturbed by both infections, disease-specificity is lacking. 
Ideally, a combination of infection-specific biomarkers should be selected as candidates for 
diagnostics. A set of validation criteria for candidate diagnostic biomarkers has been defined 
(Box 1), whereby deeper investigations on infection specificity, temporal stability, co-
infection, and human transferability have already been conducted. 
In the time trajectories (Figure 2), an overall aging effect at the small molecular weight level 
but not on lipidic larger molecular weight molecules has been observed in urine and plasma 
BOX 1 
 Specificity to infection 
 Stability over time 
 Reproducibility 
 Stability across co‐ and 
multiple infections 
 Transferability across host 
species, human particularly  
 Stability across infection 
intensity 
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(CPMG pulse program) as indicated by significant changes in the uninfected control group 
(Figure 2, A5 and C5, respectively). Since plasma analysis with the NOESY pulse program 
includes more pronounced signals from larger molecular weight compounds compared to 
CPMG, this suggests that the aging effect is mainly due to changes in small molecules. Both 
plasma data sets from P. berghei-infected mice were in agreement, whereby the main 
differences were noticed between day 1 and day 16 and between day 16 and day 19, 
correlating with the course of the infection and rapid health decline, whereas urine did not 
reflect any infection-related metabolic effect at all. The differences between day 14 and day 
19 observed in the delayed co-infection group (Figure 2, A3, B3 and C3) are consistent with 
the fact that the superinfection with the malaria parasite occurred on day 15.  
Altogether, our results largely agree with previous work on metabolic profiling of a P. berghei 
infection in NMRI mice, however, a few trends were not reproduced in the present 
investigation. For instance, we found no urinary creatinine and not the same unknown 
metabolites as did Li and colleagues (Li, Wang et al. 2008). In our study, the contribution of 
2-oxoisocaproate and 2-oxoisovalerate appeared later than 1 day post infection with P. 
berghei. Interestingly, in our results, only few traits were recognized in the urinary and 
plasma metabolic profiles of previous N. americanus hamster models, whereby both the host 
and the infectious agent differ. A hookworm-driven decrease in urinary hippurate levels had 
already been observed in correlation with N. americanus infection (Wang, Xiao et al. 2009; 
Wu, Holmes et al. 2010) as well as in trematodiases models (Saric, Li et al. 2008; Li, Holmes 
et al. 2009). Hippurate is a gut microbiotal-related metabolite (Nicholls, Mortishire-Smith et al. 
2003; Wu, Holmes et al. 2010). The metabolite 2-aminoadipate had been the most 
discriminant element in urine (Wang, Xiao et al. 2009), while it was absent in our samples. N. 
americanus induces anemia (Xue, Hui-Qing et al. 2005). Whether H. bakeri can cause 
anemia was not known (Knowles 2011), but our findings suggest that it is not the case (no 
significant difference in PCV between H. bakeri and uninfected groups) and would constitute 
a major difference between the two models. No general pattern for hookworms could be 
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identified, emphasizing that the metabolic response is strongly specific, with regard to host- 
and infective agent-specificity. 
Worm counts did not significantly vary in the presence of the P. berghei superinfection. In 
other co-infection murine models (C57Bl/6 background) between P. berghei and H. bakeri, 
no interaction was found between the pathogens and the development of cerebral malaria 
was normal (de Souza and Helmby 2008), or the Plasmodium parasitemia was exacerbated 
without changing the immunopathogenesis in cerebral malaria development (Tetsutani, 
Ishiwata et al. 2008). A meta-analysis of murine malaria-helminthiases co-infection models 
revealed a large heterogeneity of reported interactions (Knowles 2011). The authors 
suggested a dual role for helminth infections in malaria disease: in models of resolving 
malaria, the presence of the worm leads to increased mortality as the host fails to clear 
Plasmodium, and in lethal models, helminths tend to reduce host mortality (Knowles 2011).  
In the present work, no interaction has been found. We suggest that a hookworm model 
where no anemia is induced is not representative of the actual hookworm symptoms in 
humans, and therefore not representative of the stress imposed (Roche and Layrisse 1966; 
Stoltzfus, Dreyfuss et al. 1997). 
In conclusion, we found characteristic metabolic changes in the NMRI mouse urinary and 
plasma metabolic profiles due to single or co-infection with P. berghei and H. bakeri, 
reflecting the complex metabolic host-parasites cross-talk. In addition, we showed the 
capacity of 1H NMR-spectroscopy coupled with uni- and multivariate statistics to trace 
concurrent parasitic infections and highlight an inherent potential as diagnostic tool. Two 
unknown urinary metabolites have been found in correlation with P. berghei infection. In 
addition, we confirmed the presence of urinary pipecolic acid in P. berghei single and co-
infections, hence this metabolite might become a candidate diagnostic biomarker. The 
established helminth infection compensated for the plasma glucose depletion due to the 
malaria infection. No specific candidate biomarker was found for H. bakeri, most likely since 
this infection does not induce much physiological stress (i.e. due to anemia). Although no 
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interaction has been found between P. berghei and H. bakeri regarding the parasitemia and 
worm counts, this work highlights that the complexity and specificity of host-parasite 
interactions can still be reflected on the metabolic level. 
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Figure 2: Representative urine spectra. 
 
Figure 2: A = P. berghei single infection; B = delayed co-infection; C = H. bakeri single 
infection. The key to metabolite identity is the one indicated in Table 1. The water peak 
region and high peaks were cut out and indicated by double bars. 
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Figure 3: Representative plasma spectra. 
 
 
Figure 3: A = P. berghei single infection; B = delayed co-infection; C = H. bakeri single 
infection. The key to metabolite identity is the one indicated in Table 2. The aromatic region 
(δ 4.7-9), little informative, was removed. High peaks were cut out and indicated by double 
bars.
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Table 1. List of metabolites found in urine. 
URINE 
No. Metabolite δ 
1H 
(multiplicity) Day 16 Day 19 
   P/H P/CD P/C P/CS H/CD H/C H/CS CD/C CD/CS* C/CS P/H P/CD P/C P/CS H/CD H/C* H/CS CD/C CD/CS C/CS 
1 1-methylnicotinamide TA t 8.19/d 8.9/d 8.97   ↗                  
2 2-oxoisocaproate d 2.62           ↗ ↗     ↘   ↘ 
3 2-oxoisovalerate TA d 1.13                   ↘    ↘ 
4 acetate  s 1.91          ↘  ↘         
5 cholesterol TA m 0.66/m 0.79/m 0.83 ↘              ↗      
6 creatine s 3.05/s 3.93                 ↘   ↘ 
7 dimethylurea TA s 2.69          ↗           
8 formate s 8.46                 ↗ ↗  
9 hippurate s 3.97/t 7.55/t 7.64/d 7.84     ↘ ↘               
10 lactate d 1.33/q 4.11               ↘      
11 leucine t 0.96               
12 pipecolic acid m 1.68/m 1.85/ m 2.22/m 3.03           ↗   ↗ ↘   ↘ ↗  ↘ 
13 scyllo-inositol s 3.36            ↗         
14 succinate s 2.41             ↘     ↘  ↗ 
15 trimethylamine s 2.88                 ↗   
16 unknown 1 d 1.21/d 1.24 ↗  ↗  ↘  ↘ ↗  ↘ ↗  ↗  ↘   ↗  ↘ 
17 unknown 2 t 6.05/d 6.3/d 7.4/d 7.56 ↗    ↗  ↘  ↘ ↗  ↘     ↘      
 
Table 1: Arrows indicate changes in the first group cited compared to the second (i.e. P in P/H). P: P. berghei only; H: H. bakeri only; CD: delayed 
co-infection (superinfection); CS: simultaneous co-infection; C: uninfected control. s = singlet; d = doublet; t = triplet; q = quadruplet; m = multiplet. 
TA: tentatively assigned. * Bad model.  
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Table 2. List of metabolites found in plasma 
PLASMA  
No. Metabolite δ 
1H 
(multiplicity) Day 16 Day 19 
   P/H P/CD P/C P/CS H/CD H/C H/CS CD/C CD/CS C/CS P/H P/CD* P/C P/CS H/CD H/C H/CS CD/C CD/CS C/CS 
1 3-hydroxybutyrate d 1.21/m 2.32      ↘     ↘  ↘  ↗   ↘   
2 acetate s 1.91                 
3 alanine d 1.48 ↘  ↘          ↗     ↗  ↘ 
4 beta-glucose d 4.65 ↘ ↘ ↘ ↘                ↗ 
5 cholesterol TA m 0.91  ↘        ↘        
6 choline s 3.20/m 3.52 ↘  ↘ ↘         ↗ ↗       
7 creatine s 3.05/s 3.93                   
8 formate s 8.46   ↘     ↘             
9 
glucose 
t 3.42/dd 3.54/t 
3.71/dd 3.72/ddd 
3.83/m 3.84/dd 
3.91 
↘ ↘ ↘ ↘             ↗  ↗ ↗ 
10 glutamine m 2.09/m 2.45/t 3.78                  ↗  ↗ 
11 glycerol dd 3.56/dd3.64/m 3.87       ↘ ↘  ↘    ↗    ↗      ↘ 
12 glycine s 3.56    ↘         ↗   ↗  ↗   
13 glyceryl of lipids TA m 4.26  ↗               ↘   ↘ 
14 glycoprotein m 2.08 ↗  ↗                  
15 glycoprotein m 2.05               ↘   ↘ 
16 GPC s 3.23/m 4.3 ↘  ↘ ↘ ↗ ↘ ↗ ↘ ↘ ↗ ↘  ↘    ↗ ↘  ↗ 
17 isoleucine t 0.93/d 1.01 ↘    ↘           ↗     
18 lactate d 1.33/q 4.11  ↘         ↗  ↗  ↘  ↘ ↗  ↘ 
19 leucine t 0.96             ↗     ↗  ↘ 
20 lipid (CH3) m 0.88 ↗     ↘               
21 lipid (CH2CH2CH)  m 2.79      ↘ ↘  ↘  ↘  
22 lipid (CH2CH2CO) m 1.57               ↘  ↘   ↘ 
23 lipid (CH2CH2CO) m 2.23  ↗ ↗        ↘  ↗  ↘  ↘ ↗  ↘ 
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24 lipid VLDL (CH3CH2CH2C=) t 0.87 ↗      ↘               
25 lysine t 3.03 ↘  ↘  ↗ ↗    ↘           
26 myo-inositol dd 3.56/dd 3.63/t 4.06 ↘                         
27 pyruvate (TA) s 2.38                 ↘   ↘ 
28 valine d 0.99/d 1.04 ↘            ↗     ↗  ↘ 
 
Table 2: Arrows indicate changes in the first group cited compared to the second (i.e. P in P/H). P: P. berghei only; H: H. bakeri only; CD: delayed 
co-infection (superinfection); CS: simultaneous co-infection; C: uninfected control. s = singlet; d = doublet; t = triplet; q = quadruplet; m = multiplet. 
TA: tentatively assigned. * Bad model. GCP = glycerophosphocholine. 
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8. Discussion 
 
 
 
8.1. Background, objectives and key findings of the thesis 
 
Infections with soil-transmitted helminths belong to the 13 most neglected tropical diseases 
(NTDs) [1]. An infectious disease is considered “neglected” when effective, affordable and 
user-friendly drugs are lacking. Since these diseases affect the poorest people in developing 
countries, who cannot afford drugs, the pharmaceutical companies have largely ignored 
these diseases, putting an emphasis on profitable drugs [2]. Note that malaria, HIV and 
tuberculosis, all presenting market opportunities in Western countries, were no longer 
considered most neglected after the formation of public-private partnerships (PPPs) and 
substantial investments in drug research and development. However, most regrettably, the 
13 most neglected bacterial and parasitic diseases represent an insufficient incentive for the 
pharmaceutical industry to invest in drug research and development (R&D), as they have 
absolutely no rewards potential [2]. Fortunately, for some of these diseases a few PPPs 
came into play, combining industry and the public sector thus giving rise to several new drug 
R&D projects for NTDs [3]. 
Chemotherapy is still the most significant tool to control STHs. Given the restrained panel of 
“unsatisfactory” drugs available, and the potential emergence of resistance, the situation is 
considered precarious and there is an urgent need for concerted efforts to seek and develop 
new treatment options. Drug discovery and development “from scratch” is a complex, 
expensive, long and risky process and is strongly regulated. The clinical development phase 
is the most expensive step and requires solid preclinical data acting as filters before pursuing 
the endeavor [4,5].  
 
Preceding this project, a number of compounds were approved for human or veterinary 
medicine, showing anthelmintic activity and favorable prerequisites (safety, broad-spectrum, 
affordable and possible administration in single dose) [5,6,7]. As these selected drugs had 
already undergone extensive testing, they are potentially amenable to rapid development, to 
be available on the market in a few years. 
In the present work, once I had set up these nematode models at the Swiss TPH a series of 
alternative in vitro drug sensitivity assays in use for other organisms have been tested in an 
attempt to facilitate drug research against parasitic nematodes. Furthermore, the efficacies of 
four compounds have been investigated in vitro and in vivo using human STHs rodent 
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 In the hookworm models A. ceylanicum and H. bakeri, both tribendimidine and its 
active metabolite dADT displayed potent activities in vitro and in vivo. A single oral 
dose of 10 mg/kg tribendimidine reduced the A. ceylanicum worm burden by 74.8%, 
while dADT killed 87.4% of the worms at the same dose. In H. bakeri-infected mice, 
single oral doses of 2 mg/kg tribendimidine and dADT achieved worm burden 
reductions of 100% and 97.1%, respectively. In the A. ceylanicum model, the 
combination tribendimidine-levamisole displayed a promising additive to synergistic 
interaction (Chapter 4).  
 
 Nitazoxanide exhibited strong nematocidal activity against T. muris L3 and adult 
worms (IC50s = 0.27 and 12.87 µg/ml) and A. ceylanicum adult worms in vitro (IC50 = 
0.74 µg/ml). However, in both models, nitazoxanide failed to show any anthelmintic 
effect in vivo. Also, all combinations found synergistic in vitro did not decrease the 
worm burdens significantly compared to control animals in vivo (Chapter 5).  
 
 An ED50 of 4.7 mg/kg was determined for oxantel pamoate in T. muris-infected mice. 
Combined with mebendazole, a synergistic combination index (CI = 0.158) was 
calculated. Oxantel pamoate was found inefficacious against A. ceylanicum and N. 
americanus in vivo. (Chapter 6). Because the currently used drugs are not 
satisfactory in terms of efficacy against T. trichiura, oxantel pamoate and the 
promising combination with mebendazole should be further investigated. 
 
Metabolic profiling: 
 A characteristic metabolic fingerprint has been found for each of the 5 infection 
groups (P. berghei only, H. bakeri only, delayed co-infection, simultaneous co-
infection and uninfected control group).  
 
 The presence of increased levels of urinary pipecolic acid in P. berghei-infected mice 
(in single and co-infections) confirmed findings from a previous study. Two unknown 
urinary metabolites were consistently detected in all P. berghei-infected mice (in 
single and co-infections). Pipecolic acid and possibly the two unknown biomarkers 
may represent candidate diagnostic biomarkers for human malaria.   
 
Objective-specific issues have been discussed in individual chapters. The following three 
aspects were chosen for a detailed discussion here: 
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1) A few considerations on drug screening against soil-transmitted helminths and implications 
for drug discovery (section 8.2) 
 
2) Further thoughts on the current drug research situation and the means to control STHs 
(section 8.3) 
 
3) Comments on metabolic profiling as a tool for diagnosing infectious diseases (section 8.4) 
 
 
 
8.2. Considerations on drug screening for soil-transmitted 
helminthiases 
 
The use of in vitro assays to identify efficacious agents has been pivotal for anthelmintic drug 
discovery [8,9]. At present, drug screening for new compounds or assessment of drug 
resistance in field strains (at least in veterinary medicine) relies on whole-organism in vitro 
development assays, motility assays and egg hatch assays [10,11]. The motility assay 
consists of a microscopic assessment of the worms’ ability to move as a viability criterion 
[10,12]. Briefly, each adult worm is individually scored according to an arbitrary scale, 
whereas the proportion of moving infective larvae (L3, i.e. hookworm larvae), is used to 
establish the survival rate for each drug concentration. In both cases, a dose-response curve 
is plotted and a measure of efficacy (i.e. IC50) is calculated, which facilitates comparison 
between compounds [10,13]. 
 
Since cultivation of parasitic nematodes throughout their life cycles is not possible, the test 
organisms depend substantially upon sacrifice of the rodent host. Although thousands of 
hookworm and S. ratti L3 larvae can be obtained by culturing eggs released with stools of 
infected animals, additional tests on adult worms are required since both stages can present 
discrepancies in drug sensitivity. An ideal drug should show activity against both the infective 
and adult stages [5]. So far, testing on T. muris necessitates killing of the host to recover any 
stage of interest [12]. However, it might be worth mentioning that an alternative T. muris 
assay is currently being developed at the Swiss TPH. A. suum cannot be maintained in mice 
to the adult stage, and therefore testing is possible on larval stages only [14].  
 
In vivo data are the most meaningful. Besides technical limitations of in vitro systems, such 
as drug solubility in a culture medium, key factors from the host’s biology determine the 
outcome of a drug treatment. These are among others absorption, distribution and extensive 
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metabolism of the drug [15]. I would like to emphasize that the way in which soil-transmitted 
helminths take up drugs is not known (absorption through the cuticle versus ingestion), for all 
of the routinely used drugs. Especially for blood-feeders, this could have a major impact on a 
given treatment outcome, and open room for optimization of treatment and administration 
route. 
 
In some cases, in vivo results did not correspond to the effect observed in vitro. For example, 
nitazoxanide was found highly efficacious against A. ceylanicum adult worms and both 
stages of T. muris in vitro, but the effect could not be reproduced in vivo (Chapter 5). Oxantel 
pamoate exhibited anthelmintic activity against N. americanus which was not reproduced in 
vivo (Chapter 6). The contrary was observed with monepantel, where moderate efficacy 
against N. americanus in vivo would have been overlooked from the preceding negative in 
vitro data (Chapter 3). Since in vitro activity cannot always be translated into effect in vivo, 
questioning whether in vitro filters prior to in vivo testing are useful is justified.  
 
For ethical reasons and with the implementation of the 3R rules (reduce, replace, refine), it 
became important to set criteria in order to limit the use of animals to compounds presenting 
in vitro activity only. Today, the strategy of choice is still in vitro compound testing, against 
larval and adult stages (and sometimes against ova). Although it necessitates little laboratory 
equipment, the larval/adult motility assay is time-consuming, prone to the reader’s 
subjectivity and does not support high-throughput screening. This assay has proven useful in 
many cases but does not differentiate death from paralysis, the latter being reversible after 
treatment with some paralytic agents like levamisole [16,17]. The egg hatch test, commonly 
used to detect benzimidazole resistance [18], describes ovicidal activity (embryonation and 
hatching), which does not necessarily relate to anthelmintic activity against larval and adult 
stages [16,19].  
 
Because most of these methods present drawbacks [20], in vitro testing should be optimized 
to increase the quality of data and enable at least medium-throughput reading. In the present 
work, we have compared 6 different assays to the current assay of choice, the larval and 
adult motility assays for drug susceptibility testing on A. ceylanicum and T. muris (Chapter 2). 
An ideal assay should be precise, fast, affordable, highly reproducible, and require 
uncomplicated equipment with a simple (and preferably automated) readout. Such an assay 
would be a huge step forward in the field of drug discovery for parasitic nematodes. Overall, 
the xCELLigence System exhibited some of these aimed characteristics, offering a medium-
throughput automated readout, precision, and relative user-friendliness, but is suitable for A. 
ceylanicum and T. muris intestinal stages only, hence requiring dissection of the animal host. 
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For screening against T. muris, the Alamar Blue test was preferred over the xCELLigence 
System, because of its higher cost-effectiveness and extreme simplicity of the procedure. No 
examined assay was found suitable to measure the larvicidal effect on A. ceylanicum L3. 
Regrettably, the production of an instrument developed to measure the response of larval 
and adult nematodes to anthelmintic drugs, called the micromotility meter [21], has been 
stopped [22]. It was based on the angle of light refraction, which was altered by the worm’s 
movement and subsequently computer-processed. Although presenting some of the 
limitations shown by the motility assay discussed here, the readout was automated and was 
a suitable platform for medium-throughput screening [23,24]. Hopefully, additional studies 
planned in our laboratory using a microcalorimetry chip will be a step forward and will allow 
testing drug sensitivity on A. ceylanicum and T. muris precisely, quickly and simply. An 
advantage of the microcalorimetry chip is that it will enable a low consumption of biological 
test material. 
 
With the rising costs of drug development, the pharmaceutical industry experienced a 
paradigm-shift in how to conduct drug discovery and reoriented their screening strategies 
from random-compounds collections towards mechanism-based screening a few decades 
ago, a strategy that was expected to be more quickly rewarding [9,25]. Mechanism-based 
screening looks for compounds that selectively act on a well-defined receptor, using 
recombinant systems in a next step [25]. Hence, an essential prerequisite to this approach is 
a strong knowledge of the parasites’ genomes in order to identify, characterize and prioritize 
drug targets after target validation. Few genomes of parasitic nematode strains have been 
fully sequenced (only A. suum among STHs of present interest), and understanding the 
function of every gene remains as a venture. At present, this bioinformatics-based approach 
does not represent a realistic alternative to drug discovery for helminths, as much of the 
nematode biology remains to be understood and the potential targets are not sufficiently 
characterized. Indeed, the youngest class of compounds studied in the frame of this thesis, 
the AADs and its representative monepantel, discovered in the 2000s, have been identified 
by extensive in vitro whole-organism screening and monepantel exhibited the best properties 
of the 600 compounds synthesized subsequently [26]. 
 
Besides random-compound collection screening, testing marketed drugs with suggested 
anthelmintic activities via literature search or extending the spectrum of drugs in use in 
animal health appears to be a powerful strategy. In the same direction, screening large 
compound databases (i.e. DrugBank) using in silico methods will perhaps reveal to be utmost 
helpful. In this way, the support vector machines (SVM) approach predicted recently 6 
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potential anthelmintic leads targeted towards parasitic nematodes and was claimed to be 
suitable where little three-dimensional information is available about a given target [27]. 
 
In conclusion, in vitro anthelmintic activity screening is so far the only valuable strategy to 
filter compounds that deserve testing in animals, although some candidates might be missed. 
Testing of potential candidates should still be carried out on both infective larvae (if relevant) 
and adult stages. Since complementary information is gained from the different stages, one 
assay cannot replace the other. Because several compounds can be tested in different 
concentrations with the amount of worms recovered from one infected animal, in vitro testing 
on adult worms is ethical. I would recommend the use of the Alamar Blue assay for drug 
discovery against T. muris adult stages and would encourage more basic research to enable 
mechanism-based screening, a more ethical approach. If extensive whole-organism in vitro 
screening against nematodes was destined to remain, a renewed manufacture of the motility-
meter would be of great advantage. In order to identify inherent anthelmintic activity of 
existing drugs, bioinformatic methods could be an excellent start for the screening procedure 
but obviously animal models will not be easily replaceable.  
 
 
 
8.3. Drugs and control of soil-transmitted helminthiases 
 
At present, we rely on preventive chemotherapy for morbidity control in STHs endemic 
regions. In 2001, the WHO endorsed annual to biannual large-scale drug administration as 
the strategy of choice with the aim to cover at least 75% of school-aged children at risk of 
infection [28,29]. The currently restrained pharmacopeia is not satisfactory in terms of cure 
rates. Here, I would like to discuss potential novel drug candidates, the gaps hindering 
control of STHs, and the complementary strategies that can help. 
 
Although the demand is not lacking, no new drug for human use has entered the market 
since the 1970s. All of them are derived from veterinary medicine, have been translated 
without prior adjustments regarding the dosage, and relatively little is known about their 
clinical pharmacology [30]. Even if drug resistance represents no serious threat yet, an empty 
pipeline is certainly no bright strategy. The process of drug discovery and development is a 
long procedure (lasting up to 20 years [4]) and drug resistance might emerge faster than that. 
Ironically, the veterinary pharmaceutical industry is more active and has brought a few new 
drugs to the market since the 1970s [31]. Worth mentioning, criteria for animal health are 
much more stringent than actual human requirements, requiring a minimal efficacy of 90% 
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[30]. In humans, an efficacy of ≈75% (2x100 mg/kg mebendazole over 3 days, against T. 
trichiura) is accepted and there are no efficacy standards for drugs to be included in a mass 
drug administration (MDA) program [30,32].  
 
It has been proposed that the best hope of treating the world’s most neglected diseases is for 
the public sector to take responsibility for drug development, moving away from market-
driven forces [2]. On the other hand, research already suggests that the long-standing beliefs 
on NTDs drug development (nearly non-existing) activity are no longer true, and that these 
inaccurate ideas have led to a number of poorly designed government policies and 
motivations [3]. In the post-2000 era, the landscape of drug discovery for NTDs has changed 
dramatically. Indeed, the increasing formation of drug development PPPs (defined as public 
health-driven not-for-profit organizations that drive NTD drug development in conjunction with 
industry groups [3]), has allowed increasing research activity combining the manufacturing 
skills of pharmaceutical companies with the public health expertise of academia and the 
public sector, and catalyzed activity in this domain. Moreover, in the case of multinational 
drug companies (GlaxoSmithKline, Novartis, AstraZeneca and Sanofi-Aventis), money is no 
longer the driving motivation to get involved into NTDs research and development. Rather, it 
comes more from a concern for their image stemming from high pressure from the public 
sector regarding the paucity of activity for the poorest world’s needs, social responsibility and 
ethical concerns, and strategic considerations [3]. Because the PPPs usually subsidize 
further development costs (i.e. clinical trials) “no profit-no loss” partnerships are created. 
Smaller companies are active in dozens of projects, motivated by more modest, but 
profitable, commercial returns [3].  
However, so far, PPPs exist for several neglected diseases, but no PPP is dedicated to 
drugs for treating infections with soil-transmitted helminths. Only very recently, the first 
activities have started in our laboratories in collaboration with the institute for One World 
Health (mainly focused on malaria, diarrheal diseases and visceral leishmaniasis) and DNDi 
(Drugs for Neglected Diseases initiative, mainly focused on Chagas disease and human 
African trypanosomiasis). Since STHs are not their main focus, there is no guarantee that 
these new areas of interest will persist in their portfolios. Although the pipeline for STH is still 
empty, there is (cautious) reason for hope. 
 
Some of the drugs examined within the frame of this thesis were derived from veterinary 
medicine. Since, as mentioned, only scarce drug discovery efforts are ongoing for human 
helminthiases, aiming to extend the spectrum of veterinary anthelmintics is a logical 
development, encouraged by a favorably short transitioning time (3 years on average, when 
solid pre-clinical data was available [5]). Monepantel, oxantel pamoate and the 
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cyclooctadepsipeptides were three of these “low-hanging fruits” examined in our laboratories 
that showed a promising broad spectrum of activity.  
Besides discovery of novel drugs, drug combinations should be more often envisioned. 
Combining commercialized drugs represents not only a potent strategy to delay emergence 
of drug resistance, but may also eventually increase the spectra of action of the respective 
drugs on additional helminth species. In the present work, we identified two promising 
synergistic drug combinations: tribendimidine-levamisole against A. ceylanicum, and oxantel 
pamoate-mebendazole against T. muris. Additional pre-clinical trials are necessary with 
these 2 combinations. 
 
In addition to suboptimal drugs, we have suboptimal diagnostics. The pivotal role of accurate 
diagnostics at every stage of a disease control program is often neglected [33] and 
monitoring subtle changes after repeated treatments is very difficult. This lack of robust 
diagnostic tools has significant consequences, impairing the collection of precise information 
on the ecological distribution of soil-transmitted helminths, the definition of at risk populations 
and the implementation of spatially-targeted control programs [29]. In mass drug 
administration campaigns, no diagnosis is undertaken prior treatment, a decision based on 
cost-effectiveness considerations [29,34]. However, if in some places, the prevalence 
decreased sufficiently, morbidity control should be replaced by infection/transmission control, 
and integrated diagnostics would help to better refine the scope of the intervention. The 
preferred diagnostic methods rely on helminth eggs detection. Since the amount of eggs 
recovered from a stool sample is not directly related to the intensity of infection (a 
phenomenon also observed in our animal models) these diagnostic methods based on the 
demonstration of eggs in stools show poor sensitivity in low-intensity infections [35]. Only 
recently, the available methods to detect hookworm eggs were compared. For instance for 
hookworms, the Koga agar plate method performed better than Kato-Katz [36], and in 
another study, FLOTAC outperformed both methods in terms of sensitivity, but the actual egg 
counts were not equal between methods [37]. 
New robust and accurate diagnostics are needed. In 2007, only approximately US$ 58,000 
were spent on diagnostic research for STHs [38].  
 
Preventive chemotherapy does not prevent from rapid re-infection and therefore, 
complementary interventions are required to limit the frequency of infections. Improved 
access to sanitation is a rewarding key factor of integrated control programs [39,40]. In a 
recent meta-analysis, the availability and use of water supply and appropriate waste 
management revealed a protective effect on STHs, resulting in reduced transmission [39]. 
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Overall reduction of extreme poverty, but also means such as health education and hygienic 
behavior are intimately linked with decreased STH transmission [41,42]. 
 
In conclusion, control of STHs should rely on a multifactorial approach, using drugs as a 
backbone, but keeping in mind that sanitation and health education play a decisive role. 
Without proper knowledge of the drugs we use, without highly active novel drugs and without 
efficient diagnostic tools to optimize treatment strategies and monitor emergence of drug 
resistance, we are seriously ill-equipped to understand, monitor and react in case of 
emergence of drug resistance. However, I am convinced that we do have the tools to do a lot 
better, by concerting MDA efforts with sanitation improvements and strong health education 
and within reasonable expenses, by possibly combining the five standard drugs plus oxantel 
pamoate, the cyclooctadepsipeptides and tribendimidine.  
 
 
 
8.4. The use of metabolic profiling to diagnose tropical infectious 
diseases 
 
In this thesis, we aimed to acquire knowledge on metabolic profiling as a diagnostic tool in a 
mouse hookworm-malaria co-infection model. This work is one of the multiple pieces of a 
long term investigation with the aim to critically evaluate the scope and limits of 1H NMR-
based metabolic profiling as a new tool to extend our understanding of host-parasite 
interactions in general and with particular emphasis on diagnostic potential [43]. Blood 
plasma and urine samples were collected from 5 groups of mice, a P. berghei single 
infection, a H. bakeri single infection, a delayed and a simultaneous co-infection, as well as 
an uninfected control group. Our study revealed a characteristic fingerprint for each different 
group. Urinary pipecolic acid, found in a previous study in P. berghei-infected mice, may 
represent a promising candidate for human malaria diagnostics. Although further analysis will 
be required for confirmation, two potential new malaria biomarkers have been identified from 
P. berghei-infected mouse urine. These major findings and their implications are already 
discussed in Chapter 7 and here, I would like to reflect more on the potential of metabolic 
profiling as a diagnostic tool for tropical infectious diseases. 
 
The science of metabonomics has established itself as an important contributor to 
personalized healthcare which will remain a luxury of the world’s richest people [44]. For 
tropical infectious diseases, a diagnosis should be rapid and inexpensive. As mentioned 
before, development of reliable, sensitive and reproducible diagnostic tests for understanding 
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the epidemiology of tropical diseases is an integral aspect of the outcome of worldwide 
control programs and fundament to all subsequent implemented case-management or 
surveillance strategies [45]. Especially when speaking of elimination, when a disease’s 
transmission level and prevalence are very low, accurate diagnostic tools are of utmost need 
for effective active case detection [35,41,46].  
Diagnostic issues for STHs have been discussed in the section 8.3. Diagnostic approaches 
for malaria all present drawbacks. Particularly, suboptimal or inconstant detection levels are 
criticized [47,48], or the required equipment is not easy to adapt to field settings [47]. The 
malERA (Malaria Eradication Research Agenda) Consultative Group on Diagnoses and 
Diagnostics proposed a list of priorities for research and development regarding diagnostics 
[46]. The high priority-rated case-management as well as surveillance tools should be simple, 
field-applicable, minimally invasive and sensitive. Because malaria occurs in resource-poor 
settings, the cost of diagnostics should be low as well. The capacity to detect other diseases 
simultaneously, or severity markers (multiplexing) was mentioned under “medium priority”.  
1H NMR-based metabolic profiling offers several favorable characteristics. While as little as 
20 µl blood plasma is required, and obtained in humans by a simple finger prick, urine 
recovery is absolutely non-invasive [49]. Both matrices are metabolically rich and well-
characterized across several species [50,51,52]. In addition, the method undoubtedly holds 
promise to detect disease severity markers and multiple species at one time, with reasonable 
sensitivity. The major disadvantages of this technique are on the one hand the risk of 
spectral overlaps, compromising the identification of the multiple species at play, and on the 
other hand the cost of equipment, the required infrastructure and the high level of skills 
necessitated for interpretation of the spectra. To solve the latter problem to some extent, 
there may be scope for implementation of analytic platforms that are less expensive than 
NMR (like HPLC-MS) in some chosen laboratories in endemic countries [53].  
 
The quality and quantity of biomarkers are important for the choice of a suitable diagnostic 
template but do not conclusively elucidate how well a disease is reflected by them [43]. The 
specificity of a biomarker to any disease is the most difficult point to uncover and extensive 
evaluation across several species is required [43]. Although identification of a single specific 
biomarker would be ideal, the use of multiple biomarkers would improve diagnostic accuracy 
[54].  
How useful rodent metabolic biomarkers are transposable from laboratory-controlled models 
to humans still needs to be better defined. In human populations, the inter- and intra-
individual variability is more pronounced. The age and gender, the intensity of infection as 
well as nutritional status etc. impact the individual metabolic profile and might render the 
interpretation difficult. In a study with Schistosoma mansoni-infected human subjects in 
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Uganda [55], a good overlap with metabolic fingerprints in previous animal studies was 
observed, suggesting the existence of a specific metabolic response to this infection [56]. In 
a study based on Onchocerca volvulus-infected patients, 14 discriminating candidate 
biomarkers (showing sensitivity and specificity of >99%) have been identified using LC-MS-
based metabolic profiling [57]. The sensitivity of the method was such that the authors 
mentioned the eventual possibility to monitor worms’ viability in the patient following 
treatment. A P. vivax metabonomic investigation using urine from infected patients revealed 
the potential of differentiation between malarial versus non-malarial fevers, due to 
discriminant biomarkers [58]. Overall, the authors proposed additional human studies to 
confirm this specificity and to validate the test against the widest genetic backgrounds 
possible.  
Ultimately, the optimized biomarkers can be transposed into field-ready portable diagnostic 
tests such as immunochromatographic, microfluidic-based tests or lab-on-chip technologies 
[57,59]. 
 
In conclusion, the use of metabolic profiling is a powerful approach to identify disease-related 
metabolic fingerprints, delivering a holistic read-out on one individual’s health. With the 
growing knowledge about biomarkers from animal models but also studies in the field, the 
use of metabolic-based diagnostics may be on the horizon. However, given the high price of 
the necessary equipment and the complexity of interpretation of the spectra, a mandatory 
prerequisite to apply this technology to diagnostics for tropical infectious diseases would be 
the transformation into a simple biochemical assay: ideally a dipstick or lab-on-chip 
technology. This is in itself a new endeavor. 
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9. Conclusion and Outlook 
 
 
In this thesis, several aspects in research on soil-transmitted helminths have been 
addressed: the optimization of in vitro drug screening assays, the characterization of the 
efficacy of potential novel drug candidates, and the investigation of a potential diagnostic 
tool.  
For T. muris, one alternative in vitro assay, the Alamar Blue assay, compared favorably to 
the standard motility assay. 
Fortunately, out of four examined compounds, one drug has been positively evaluated for its 
trichuricidal properties (oxantel pamoate), one for promising anti-hookworm effects 
(tribendimidine) and two potent drug combinations have been uncovered (tribendimidine-
levamisole and oxantel pamoate-mebendazole). Two drugs failed to show sufficient activity 
(monepantel and nitazoxanide). 
1H NMR spectroscopy was found to be powerful for detecting metabolic changes in a co-
infection model, but the identified biomarkers would necessitate validation across other 
species (in particular transferability to humans) and transposition into a field-applicable 
format (such as a dipstick) in order to present a realistic option for diagnostics. 
 
I am convinced that drug combinations are an accessible and extremely powerful tool to 
control STHs. Unfortunately, they are still scandalously overlooked. Policy-makers need to 
review their positions not only regarding the few but strong efforts to discover and develop 
new drugs, but also by recognizing the “low-hanging fruits” represented by combined 
chemotherapy (first between approved drugs, including novel drugs then). 
It is largely accepted that long-term control will stem from several sides and that missing 
knowledge from precise epidemiological data, drug pharmacology and worm physiology are 
impeding implemented strategies. Further research is needed to fill all these gaps.  
 
In some bullet points, I would like to list a few study directions which may constitute logical 
next steps to this work: 
 
 Further pre-clinical studies should be carried out with the additive/synergistic drug 
combinations identified here. For example, drug interaction studies are desirable. 
 Investigations on drug uptake by the worms (ongoing in our laboratory). 
 Identification of the urinary unknown metabolites found consistently in all P. berghei-
infected mouse groups (ongoing) and evaluation of transferability through species 
(e.g. P. falciparum) and of stability through infection intensities. 
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